

524 Reed PCT/PTO 01 NOV 1999.

Certificate of Mailing


Date of Deposit November 1, 1999

Label Number: EJ770212859US

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX PCT, Assistant Commissioner of Patents, Washington, D.C. 20231.

Luis A. Cruz

Printed name of person mailing correspondence



Signature of person mailing correspondence


| Substitute Form PTO 1390 U.S. Department of Commerce Patent and Trademark Office  |                                     |   | Attorney's Docket Number:<br>50019/006001    |
|---|-------------------------------------|---|--|
| TRANSMITTAL LETTER TO THE UNITED STATES<br>DESIGNATED/ELECTED OFFICE (DO/EO/US)<br>CONCERNING A FILING UNDER 35 U.S.C. 371      |                                     |   | U.S. Application Number:<br>Not Yet Assigned |
| INTERNATIONAL APPLICATION NUMBER  | INTERNATIONAL FILING DATE           | PRIORITY DATE CLAIMED   |  |
| PCT/FR98/00875  | 30 April 1998                       | 30 September 1997<br>8 December 1997  |  |
| TITLE OF INVENTION:   |                                     | ANTI- <i>HELICOBACTER</i> VACCINE COMPOSITION COMPRISING A TH1-TYPE ADJUVANT  |  |
| APPLICANTS FOR DO/EO/US:  |                                     | Bruno Guy and Jean Haensler   |  |
| Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: |                                     |   |  |
| 1.  | <input checked="" type="checkbox"/> | This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.  |  |
| 2.  | <input type="checkbox"/>            | This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.   |  |
| 3.  | <input checked="" type="checkbox"/> | This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). |  |
| 4.  | <input checked="" type="checkbox"/> | A proper Demand for International Preliminary Examination was made by the 19 <sup>th</sup> month from the earliest claimed priority date.   |  |
| 5.  | <input checked="" type="checkbox"/> | A copy of the International Application as filed (35 U.S.C. 371(c)(2)).   |  |
| a.  | <input type="checkbox"/>            | is transmitted herewith (required only if not transmitted by the International Bureau).   |  |
| b.  | <input type="checkbox"/>            | has been transmitted by the International Bureau.   |  |
| c.  | <input type="checkbox"/>            | is not required, as the application was filed with the United States Receiving Office (RO/US).  |  |
| 6.  | <input checked="" type="checkbox"/> | A translation of the International Application into English (35 U.S.C. 371(c)(2)).  |  |
| 7.  | <input checked="" type="checkbox"/> | Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).   |  |
| a.  | <input checked="" type="checkbox"/> | are transmitted herewith (required only if not transmitted by the International Bureau).  |  |
| b.  | <input type="checkbox"/>            | have been transmitted by the International Bureau.  |  |
| c.  | <input type="checkbox"/>            | have not been made; however, the time limit for making such amendments has NOT expired.   |  |
| d.  | <input type="checkbox"/>            | have not been made and will not be made.  |  |
| 8.  | <input checked="" type="checkbox"/> | A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).   |  |
| 9.  | <input checked="" type="checkbox"/> | An oath or declaration of the inventors (35 U.S.C. 371(c)(4)). (unsigned)   |  |

SEARCHED 7/9/2004

09/4039 67  
514 Rec'd PCT/PTO 01 NOV 1999

|   |  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
|---|--|--------------|------------|---|-----------|--|-----------|---|-----------|--|-----------|---|----------|--------|--------------|--------------|------|--------------|-----------|---|-----------|--------------------|---------|---|-----------|---|--|--|------------|---|--|--|--|---|--|--|--|---------------|--|--|--|---|--|--|--|-------------------------|--|--|--|---|--|--|--|-----------------------------------|--|--|--|--------------------------|--|--|--|------------|--|--|--|
| 11.   | An Information Disclosure Statement under 37 CFR 1.97 and 1.98.  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| 12.   | An assignment for recording. A separate cover sheet in compliance with 37 3.28 and 3.31 is included.   |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| 13. X   | A FIRST preliminary amendment.   |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
|   | A SECOND or SUBSEQUENT preliminary amendment.  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| 14.   | A substitute specification.  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| 15.   | A change of power of attorney and/or address letter.   |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| 16. X   | Other items or information: Postcard, two certified copies of priority documents; English translations of priority documents   |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| 17.   | <p>The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492(A)(1)-(5)):</p> <table> <tr> <td>Search Report has been prepared by the EPO or JPO</td> <td>\$ 840.00</td> </tr> <tr> <td>International preliminary examination fee paid to USPTO (37 CFR 1.492)</td> <td>\$ 670.00</td> </tr> <tr> <td>No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee (37 CFR 1.445(a)(2)) paid to USPTO</td> <td>\$ 760.00</td> </tr> <tr> <td>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO</td> <td>\$ 970.00</td> </tr> <tr> <td>International preliminary examination fee paid to USPTO (37 CFR 1.492) and all claims satisfied provisions of PCT Article 33(2)-(4)</td> <td>\$ 96.00</td> </tr> </table> <p>ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 970.00</p> <p>Surcharge of \$130 for furnishing the oath or declaration later than <input type="checkbox"/> 20 OR <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table> <tr> <td>CLAIMS</td> <td>NUMBER FILED</td> <td>NUMBER EXTRA</td> <td>RATE</td> </tr> <tr> <td>Total claims</td> <td>28 - 20 =</td> <td>8</td> <td>x \$22.00</td> </tr> <tr> <td>Independent claims</td> <td>3 - 3 =</td> <td>0</td> <td>x \$82.00</td> </tr> <tr> <td colspan="3">Multiple dependent claims (if applicable)</td> <td>+ \$260.00</td> </tr> <tr> <td colspan="4">TOTAL OF ABOVE CALCULATIONS = \$ 1,146.00</td> </tr> <tr> <td colspan="4">Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed with this request (Note 37 CFR 1.9, 1.27, 1.28).</td> </tr> <tr> <td colspan="4">SUBTOTAL = \$</td> </tr> <tr> <td colspan="4">Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 OR <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</td> </tr> <tr> <td colspan="4">TOTAL NATIONAL FEE = \$</td> </tr> <tr> <td colspan="4">Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.</td> </tr> <tr> <td colspan="4">TOTAL FEES ENCLOSED = \$ 1,146.00</td> </tr> <tr> <td colspan="4">Amount to be refunded \$</td> </tr> <tr> <td colspan="4">charged \$</td> </tr> </table> |              |            | Search Report has been prepared by the EPO or JPO | \$ 840.00 | International preliminary examination fee paid to USPTO (37 CFR 1.492) | \$ 670.00 | No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee (37 CFR 1.445(a)(2)) paid to USPTO | \$ 760.00 | Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO | \$ 970.00 | International preliminary examination fee paid to USPTO (37 CFR 1.492) and all claims satisfied provisions of PCT Article 33(2)-(4) | \$ 96.00 | CLAIMS | NUMBER FILED | NUMBER EXTRA | RATE | Total claims | 28 - 20 = | 8 | x \$22.00 | Independent claims | 3 - 3 = | 0 | x \$82.00 | Multiple dependent claims (if applicable) |  |  | + \$260.00 | TOTAL OF ABOVE CALCULATIONS = \$ 1,146.00 |  |  |  | Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed with this request (Note 37 CFR 1.9, 1.27, 1.28). |  |  |  | SUBTOTAL = \$ |  |  |  | Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 OR <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)). |  |  |  | TOTAL NATIONAL FEE = \$ |  |  |  | Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property. |  |  |  | TOTAL FEES ENCLOSED = \$ 1,146.00 |  |  |  | Amount to be refunded \$ |  |  |  | charged \$ |  |  |  |
| Search Report has been prepared by the EPO or JPO   | \$ 840.00  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| International preliminary examination fee paid to USPTO (37 CFR 1.492)  | \$ 670.00  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee (37 CFR 1.445(a)(2)) paid to USPTO   | \$ 760.00  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  | \$ 970.00  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| International preliminary examination fee paid to USPTO (37 CFR 1.492) and all claims satisfied provisions of PCT Article 33(2)-(4)   | \$ 96.00   |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| CLAIMS  | NUMBER FILED   | NUMBER EXTRA | RATE       |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| Total claims  | 28 - 20 =  | 8            | x \$22.00  |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| Independent claims  | 3 - 3 =  | 0            | x \$82.00  |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| Multiple dependent claims (if applicable)   |  |              | + \$260.00 |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| TOTAL OF ABOVE CALCULATIONS = \$ 1,146.00   |  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed with this request (Note 37 CFR 1.9, 1.27, 1.28).   |  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| SUBTOTAL = \$   |  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 OR <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)). |  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| TOTAL NATIONAL FEE = \$   |  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.                                   |  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| TOTAL FEES ENCLOSED = \$ 1,146.00   |  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| Amount to be refunded \$  |  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |
| charged \$  |  |              |            |   |           |  |           |   |           |  |           |   |          |        |              |              |      |              |           |   |           |                    |         |   |           |   |  |  |            |   |  |  |  |   |  |  |  |               |  |  |  |   |  |  |  |                         |  |  |  |   |  |  |  |                                   |  |  |  |                          |  |  |  |            |  |  |  |

09/403967  
514 Rec'd PCT/PTO 01 NOV 1999

|  |   |   |
|--|---|---|
| a.   | X | A check in the amount of \$ 1,146.00 to cover the above fees is enclosed.   |
| b.   |   | Please charge my Deposit Account No. 03-2095 in the amount of \$ [*.*] to cover the above fees.   |
| c.   | X | The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 03-2095. A duplicate copy of this sheet is enclosed. |
| NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.   |   |   |
| SEND ALL CORRESPONDENCE TO:  |   |   |
| <p>Paul T. Clark<br/>Clark &amp; Elbing LLP<br/>176 Federal Street<br/>Boston, MA 02110-2214</p> <p>Telephone: 617-428-0200<br/>Facsimile: 617-428-7045</p>  |   |   |
| <p><br/>_____<br/>Signature<br/>Paul T. Clark<br/>Reg No. 30,162</p> <p><br/>_____<br/>Susan M. Michaud<br/>Reg. No 42,885</p> |   |   |

\Ceserver\documents\50019\50019.006001 U.S. National Application.wpd

DRAFTING DOCUMENTS

\Ceserver\documents\50019\50019.006001 U.S. National Application.wpd

Revised: 5 September 1997

PATENT  
ATTORNEY DOCKET NO. 50019/006001

## Certificate of Mailing

Date of Deposit: March 28, 2000Label Number: EL488650525US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX PCT, Assistant Commissioner for Patents, Washington, D.C. 20231.

Luis A. Cruz

Printed name of person mailing correspondence

Signature of person mailing correspondence

## IN THE UNITED STATES RECEIVING OFFICE

Applicant: Bruno Guy et al. Art Unit:

Serial No.: 09/403,967 Examiner:  
(based on International  
Application PCT/FR98/00875,  
filed April 30, 1998)

Filed: November 1, 1999

Title: Anti-Helicobacter Vaccine Composition Comprising a TH1-Type  
AdjuvantBOX PCT  
Assistant Commissioner for Patents  
Washington, D.C. 20231PRELIMINARY AMENDMENT

Prior to examination of the above-captioned patent application, kindly amend the application as follows.

In the Claims:

Cancel claims 1-28 and add the following new claims 29-58.

03/31/2000 PVO/LPE 00009929 08403867 A pharmaceutical composition comprising an immunogenic agent derived


01 FC:154  
02 FC:966130.00 OP  
36.00 GP

from Helicobacter and a compound that promotes induction of a T helper 1-type immune response against Helicobacter, said compound being selected from the group consisting of:

(i) a saponin purified from an extract of *Quillaja saponaria*;

(ii) a cationic lipid or a salt thereof, wherein said lipid is a weak inhibitor of protein kinase C and has a structure that comprises a lipophilic group derived from cholesterol, a bonding group selected from carboxyamides and carbamoyls, a spacer arm consisting of a branched or unbranched linear alkyl chain of 1 to 20 carbon atoms, and a cationic amine group selected from primary, secondary, tertiary, and quaternary amines, and said lipid is not provided in the form of a liposome when the composition does not comprise a saponin or a glycolipopeptide of formula (I); and

(iii) a glycolipopeptide of formula (I):



in which

R<sup>1</sup> represents an alkyl group that is saturated or unsaturated once or several times and comprises 1 to 50 carbon atoms;

X represents -CH<sub>2</sub>- , -O- , or -NH-;

R<sup>2</sup> represents a hydrogen atom or an alkyl group that is saturated or unsaturated

once or several times and comprises 1 to 50 carbon atoms;

R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> each represent, independently of each other, a hydrogen atom or an acyl-CO-R<sup>6</sup> group, in which R<sup>6</sup> represents an alkyl group comprising 1 to 10 carbon atoms;

R<sup>7</sup> represents a hydrogen atom or a C<sub>1</sub>-C<sub>7</sub> alkyl, hydroxymethyl, 1-hydroxyethyl, mercaptomethyl, 2-(methylthio)ethyl, 3-aminopropyl, 3-ureidopropyl, 3-guanidylpropyl, 4-aminobutyl, carboxymethyl, carbamoylmethyl, 2-carboxyethyl, 2-carbamoylethyl, benzyl, 4-hydroxybenzyl, 3-indolylmethyl, or 4-imidazolylmethyl group;

R<sup>8</sup> represents a hydrogen atom or a methyl group; and

R<sup>9</sup> represents a hydrogen atom or an acetyl, benzoyl, trichloroacetyl, trifluoroacetyl, methoxycarbonyl, t-butyloxycarbonyl, or benzyloxycarbonyl group.--

--30. The composition of claim 29, wherein R<sup>7</sup> and R<sup>8</sup>, when taken together, represent a -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>- group.--

--31. The composition of claim 29, comprising a first and a second compound, said first compound being a saponin purified from an extract of *Quillaja saponaria* and said second compound being a cationic lipid or a salt thereof, wherein said lipid is a weak inhibitor of protein kinase C and has a structure that comprises a lipophilic group derived from cholesterol, a bonding group selected from carboxyamides and carbamoyls, a spacer

arm consisting of a branched or unbranched linear alkyl chain of 1 to 20 carbon atoms, and a cationic amine group selected from primary, secondary, tertiary, and quaternary amines.--

--32. The composition of claim 29, wherein the compound is a saponin that is present in the QS-21 fraction purified from a *Quillaja saponaria* extract.--

--33. The composition of claim 29, wherein the compound is a cationic lipid made in the form of a dispersion.--

--34. The composition of claim 29, wherein the compound is the cationic lipid 3-beta-[N-(N',N'-dimethylaminoethane)carbamoyl]cholesterol (DC-chol) or a salt thereof.--

--35. The composition of claim 29, wherein the compound is the glycolipopeptide N-(2-L-leucin-amido-2-deoxy-(D-glucopyranosyl)N-octadecyl-dodecanoylamide (Bay R1005).--

--36. The composition of claim 29, wherein the immunogenic agent derived from *Helicobacter* is selected from the group consisting of a preparation of inactivated

Helicobacter bacteria, a Helicobacter cell lysate, and a peptide or a polypeptide from Helicobacter in purified form.--

--37. The composition of claim 36, wherein the immunogenic agent derived from Helicobacter comprises the UreB or UreA subunit of Helicobacter urease.--

--38. The composition of claim 29, wherein the immunogenic agent derived from Helicobacter is derived from *Helicobacter pylori*.--


--39. A method of inducing a T helper 1-type immune response against Helicobacter in a patient, said method comprising administering to the patient an immunogenic agent derived from Helicobacter and a compound that promotes induction of a T helper 1-type immune response against Helicobacter, said compound being selected from the group consisting of:

(i) a saponin purified from an extract of *Quillaja saponaria*;

(ii) a cationic lipid or a salt thereof, wherein said lipid is a weak inhibitor of protein kinase C and has a structure that comprises a lipophilic group derived from cholesterol, a bonding group selected from carboxyamides and carbamoyls, a spacer arm consisting of a branched or unbranched linear alkyl chain of 1 to 20 carbon atoms, and a cationic amine group selected from primary, secondary, tertiary, and quaternary amines,

and said lipid is not provided in the form of a liposome when the composition does not comprise a saponin or a glycolipopeptide of formula (I); and

(iii) a glycolipopeptide of formula (I):



in which

R<sup>1</sup> represents an alkyl group that is saturated or unsaturated once or several times and comprises 1 to 50 carbon atoms;

X represents -CH<sub>2</sub>-, -O-, or -NH-;

R<sup>2</sup> represents a hydrogen atom or an alkyl group that is saturated or unsaturated once or several times and comprises 1 to 50 carbon atoms;

R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> each represent, independently of each other, a hydrogen atom or an acyl-CO-R<sup>6</sup> group, in which R<sup>6</sup> represents an alkyl group comprising 1 to 10 carbon atoms;

R<sup>7</sup> represents a hydrogen atom or a C<sub>1</sub>-C<sub>7</sub> alkyl, hydroxymethyl, 1-hydroxyethyl, mercaptomethyl, 2-(methylthio)ethyl, 3-aminopropyl, 3-ureidopropyl, 3-guanidylpropyl, 4-aminobutyl, carboxymethyl, carbamoylmethyl, 2-carboxyethyl, 2-carbamoyleethyl, benzyl, 4-hydroxybenzyl, 3-indolylmethyl, or 4-imidazolylmethyl group;

R<sup>8</sup> represents a hydrogen atom or a methyl group; and

R<sup>9</sup> represents a hydrogen atom or an acetyl, benzoyl, trichloroacetyl, trifluoroacetyl, methoxycarbonyl, t-butyloxycarbonyl, or benzyloxycarbonyl group.--

--40. The method of claim 39, wherein R<sup>7</sup> and R<sup>8</sup>, when taken together, represent a -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>- group.--

--41. The method of claim 39, wherein an immunogenic agent derived from Helicobacter and two compounds are administered to said patient, said first compound being a saponin purified from an extract of *Quillaja saponaria* and said second compound being a cationic lipid or a salt thereof, said lipid being a weak inhibitor of protein kinase C and having a structure that comprises a lipophilic group derived from cholesterol, a bonding group selected from carboxyamides and carbamoyls, a spacer arm consisting of a branched or unbranched linear alkyl chain of 1 to 20 carbon atoms, and a cationic amine group selected from primary, secondary, tertiary and quaternary amines.--

--42. The method of claim 39, wherein the compound is a saponin that is present in the QS-21 fraction purified from a *Quillaja saponaria* extract.--

--43. The method of claim 39, wherein the compound is a cationic lipid made in the form of a dispersion.--

--44. The method of claim 39, wherein the compound is the cationic lipid 3-beta-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-chol) or a salt thereof.--

--45. The method of claim 39, wherein the compound is the glycolipopptide N-(2-L-leucin-amido-2-deoxy-(-D-glucopyranosyl) N-octadecyl-dodecanoyleamide (Bay R1005).--

--46. The method of claim 39, wherein the T helper 1-type immune response is measured in mice and is characterized by a ratio of ELISA IgG2a:IgG1 titres that is greater than or equal to 1:20, the IgG2a and IgG1 being immunoglobulins induced against Helicobacter.--

--47. The method of claim 46, wherein the T helper 1-type immune response is characterized by a ratio of ELISA IgG2a:IgG1 titres that is greater than or equal to 1:10.--

--48. The method of claim 47, wherein the T helper 1-type immune response is characterized by a ratio of ELISA IgG2a:IgG1 titres that is greater than or equal to 1:2.--

--49. The method of claim 39, wherein the immunogenic agent derived from

Helicobacter is selected from the group consisting of a preparation of inactivated Helicobacter bacteria, a Helicobacter cell lysate, and a peptide or a polypeptide from Helicobacter in purified form.--

--50. The method of claim 49, wherein the immunogenic agent derived from Helicobacter comprises the UreB or UreA subunit of Helicobacter urease.--

--51. The method of claim 39, wherein the immunogenic agent derived from Helicobacter is derived from *Helicobacter pylori*.--

--52. The method of claim 39, wherein the immunogenic agent and the compound are administered to the patient by a systemic route.--

--53. The method of claim 52, wherein the systemic route is the strict systemic route.--

--54. The method of claim 52, wherein the immunogenic agent and the compound are administered to the patient by a systemic route in a region of the patient that is situated under its diaphragm.--

--55. The method of claim 52, wherein the immunogenic agent and the compound are administered to the patient by a systemic route in the dorsolumbar region of the patient.--

--56. The method of claim 52, wherein the systemic route is selected from the group consisting of the subcutaneous route, the intramuscular route, and the intradermal route.--

--57. The method of claim 39, wherein the immunogenic agent and the compound are administered to the patient twice or three times by a systemic route during the same treatment.--

--58. A method of inducing a T helper 1-type immune response against Helicobacter in a patient, said method comprising administering to the patient a compound that promotes induction of a T helper 1-type immune response against Helicobacter in the patient.--

REMARKS

The amendments set forth above are being made to bring the claims into conformity with U.S. patent practice. No new matter has been added in these amendments.

Although no charges are believed to be due, if there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: March 15, 2000

  
\_\_\_\_\_  
Paul T. Clark                    Susan M. Michaud  
Reg. No. 30,162                Reg. No. 42,885

Clark & Elbing LLP  
176 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

\W\N\server\documents\50019\50019\_006001\_preliminary amendment 2.wpd

09/403967  
514 Rec'd PCT/PTO 01 NOV 1999

PATENT

ATTORNEY DOCKET NO. 50019/006001

Certificate of Mailing


Date of Deposit: November 1, 1999

Label Number: EJ770212859US

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PCT, Assistant Commissioner of Patents, Washington, D.C. 20231.

Luis Cruz

Printed name of person mailing correspondence

  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bruno Guy *et al.*

Art Unit: Not Yet Assigned

Serial No.: Not Yet Assigned

Examiner: Not Yet Assigned

Filed: November 1, 1999

Title: Anti-Helicobacter Vaccine Composition Comprising a TH1-Type Adjuvant

BOX PCT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Docket No. 50019/006001

PRELIMINARY AMENDMENT

Prior to examination of the above-captioned patent application, which is being filed herewith, kindly amend the application as follows.

In the Claims:

Amend claims 5, 7, 9, 14, 16, 19, 21, 22, and 24-27 as follows.

5. (Amended) Composition according to Claim 1 [or 4], in which the compound is

a cationic lipid which is

3-beta-[N-(N',N'-dimethylaminoethane)carbamoyl]cholesterol(DC-chol) or a salt of the latter.

7. (Amended) Composition according to Claim 1 [one of Claims 1 to 6], in which the immunogenic agent derived from Helicobacter is selected from a preparation of inactivated Helicobacter bacteria, a Helicobacter cell lysate, a peptide and a polypeptide from Helicobacter in purified form.

9. (Amended) Composition according to Claim 1 [one of Claims 1 to 8], in which the immunogenic agent is derived from Helicobacter pylori.

14. (Amended) Use according to Claim 10 [or 13], in which the compound is 3-beta-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-chol) or a salt of the latter.

16. (Amended) Use according to Claim 10 [one of Claims 10 to 15], in which the Th1 type immune response is measured in mice and is characterized by a ratio of the ELISA IgG2a : IgG1 titres greater than or equal to 1 : of the ELISA IgG2a : IgG1 titres greater than or equal to 1 : 20; the IgG2a and IgG1 being immunoglobulins induced

against Helicobacter.

19. (Amended) Use according to Claim 10 [one of Claims 10 to 18], in which the immunogenic agent derived from Helicobacter is selected from a preparation of inactivated Helicobacter bacteria, a Helicobacter cell lysate, a peptide and a polypeptide from Helicobacter in purified form.

21. (Amended) Use according to Claim 10 [one of Claims 10 to 20], in which the immunogenic agent is derived from Helicobacter pylori.

22. (Amended) Use according to Claim 10 (one of Claims 10 to 21), in which the pharmaceutical composition is intended to be administered by the systemic route.

24. (Amended) Use according to Claim 22 [or 23], in which the pharmaceutical composition is intended to be administered by the systemic route in the part of a mammal, in particular of a primate, situated under its diaphragm.

25. (Amended) Use according to Claim 22 (one of Claims 22 to 24), in which the pharmaceutical composition is intended to be administered by a systemic route in the dorsolumbar region of a mammal, in particular a primate.

26. (Amended) Use according to Claim 22 (one of Claims 22 to 25), in which the pharmaceutical composition is intended to be administered by a systemic route selected from the subcutaneous route, the intramuscular route and the intradermal route.

27. (Amended) Use according to Claim 10 [one of Claims 10 to 26], in which the pharmaceutical composition is intended to be administered twice or three times by the systemic route during the same treatment, to prevent or treat a Helicobacter infection.

#### CONCLUSION

Although no charges are believed to be due, if there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: November, 1999

Susan M. Michaud  
Paul T. Clark      Susan M. Michaud  
Reg. No. 30,162      Reg. No. 42,885

Clark & Elbing LLP  
176 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045  
\\Ceserver\\documents\\50019\\50019.006001 preliminary amendment wpd

Anti-*Helicobacter* vaccine composition comprising a  
Th1-type adjuvant

The subject of the present invention is the  
5 specific use of a vaccine preparation intended to induce, in a mammal, a protective immune response against a pathogenic organism infecting the mucous membranes, in particular against *Helicobacter* bacteria.

*Helicobacter* is a bacterial genus characterized  
10 by Gram-negative helical bacteria. Several species colonize the gastrointestinal tract of mammals. There may be mentioned in particular *H. pylori*, *H. heilmanni*, *H. felis* and *H. mustelae*. Although *H. pylori* is the species most commonly associated with human infections, 15 in some rare cases, it has been possible to isolate in man *H. heilmanni* and *H. felis*. A bacterium of the *Helicobacter* type, *Gastrospirillum hominis*, has also been described in man.

*Helicobacter* infects more than 50% of the adult  
20 population in developed countries and nearly 100% of that of developing countries, thereby making it one of the predominant infectious agents worldwide.

*H. pylori* is so far exclusively found at the surface of the mucous membrane of the stomach in man  
25 and more particularly around the crater lesions of gastric and duodenal ulcers. This bacterium is currently recognized as the aetiological agent of antral gastritis and appears as one of the cofactors required for the development of ulcers. Moreover, it seems that the development of gastric carcinomas may be 30 associated with the presence of *H. pylori*.

It therefore appears to be highly desirable to develop a vaccine intended to prevent or treat *Helicobacter* infections.

35 To date, several *Helicobacter* proteins have already been proposed as vaccinal antigen and the method of vaccination which is commonly recommended

consists in delivering the antigen at the level of the gastric mucous membrane, that is to say at the very site where the immune response is desired. To do this, oral administration was therefore selected.

5 [lacuna] other than the gastric mucous membrane, such as the nasal or rectal mucous membrane for example (WO 96/31235). Lymphocytes stimulated by the antigen in a so-called inducer mucosal territory can migrate and circulate selectively so as to go and  
10 induce an immune response in other so-called effector mucosal territories.

A variant of these methods consists in carrying out a first immunization by the systemic route before administering the antigen by the nasal route.

15 For administration by the mucosal route, the antigen, most often a bacterial lysate or a purified protein, is combined with an appropriate adjuvant such as the cholera toxin (CT) or the heat-labile toxin (LT) from *E. coli*.

20 When the administration by the mucosal route is used, the humoral response which is observed is predominantly of the IgA type. This indeed indicates that there has been a local immune response.

Some authors thought very early on that there  
25 was a good correlation between a strong response of the IgA type and a protective effect (Czinn et al., Vaccine (1993) 11: 637). Others gave a more reserved opinion (Bogstedt et al., Clin. Exp. Immunol. (1996) 105: 202). Although there is up until now no real certainty as  
30 regards this subject, the induction of antibodies which are in particular of the IgA type appears nonetheless desirable for most authors.

In general, the appearance of IgAs is indicative of the coming into play of a response on the  
35 part of the type 2 T helper lymphocytes (Th2 response).

Indeed, the stimulation of the T helper lymphocytes by a particular antigen makes it possible

The Th1 cells in particular produce selectively interleukin-2 (IL-2) and interferon- $\gamma$  (IFN- $\gamma$ ), whereas the Th2 cells secrete preferably IL-4, -5 and -10. Because of their differentiated production of cytokines, these two types of T helper cells have distinct roles: the Th1 cells promote cell-mediated immunity i.a. an inflammatory-type response, whereas the Th2 cells stimulate humoral response of the IgA, IgE and certain IgG subclass types. It is also known that the cytokines produced by mouse Th1 cells can stimulate antibody response and in particular that IFN- $\gamma$  induces an IgG2a response.

Thus, from the various studies in the prior art, the view emerges according to which the induction 15 of a Th2 response characterized by the appearance of IgA is essential, if not enough, to obtain a protective effect.


Surprisingly, it has now been discovered that even if a Th2 response is not damaging, it is also 20 necessary to induce a high Th1 response. Indeed, experimental results now demonstrate that a protective effect may be more easily correlated with a Th1 response than with a Th2 response.

Contrary to what was initially sought (D'Elios 25 et al., J. Immunol. (1997) 158: 962), the present application therefore reveals the importance of inducing an inflammatory-type Th1 response at the time of immunization, without which a protective effect cannot be observed.

It is possible to induce a Th1 response against 30 *Helicobacter* by adjusting a number of factors, such as, for example, the type of adjuvant. It has indeed been demonstrated that by using certain adjuvants, a level of protection can be obtained which is similar to or 35 greater than that observed when the mucosal route and adjuvants such as bacterial toxins are used.

Consequently, the subject of the present invention is:

- 5           (a) The conjoint use of an immunogenic agent derived from *Helicobacter* and of a compound capable of promoting the induction of a T helper 1 (Th1) type immune response against *Helicobacter*, in the manufacture of a medicament intended to be administered by the systemic route to prevent or treat a *Helicobacter* infection.
- 10          (b) A pharmaceutical composition which comprises an immunogenic agent derived from *Helicobacter* and at least one compound (capable of promoting the induction of a T helper 1 (Th1) type immune response against *Helicobacter*) selected from:
- 15          (i) saponins purified from an extract of *Quillaja saponaria*;
- 20          (ii) cationic lipids or a salt of the latter; the said lipids being weak inhibitors of protein kinase C and having a structure which includes a lipophilic group derived from cholesterol, a bonding group selected from carboxyamides and carbamoyls, a spacer arm consisting of a branched or unbranched linear alkyl chain of 1 to 20 carbon atoms, and a cationic amine group selected from primary, secondary, tertiary and quaternary amines, on condition that these lipids are not provided in the form of liposomes when the said composition contains no saponin or glycolipopeptide of formula (I); and
- 25          (ii) glycolipopeptides of formula (I):



in which:

|    |  |  |
|----|--|--|
|    | R <sup>1</sup>                                     | represents an alkyl residue saturated or unsaturated once or several times and comprising from 1 to 50 carbon atoms, preferably 1 to 20 carbon atoms,  |
| 5  | X  | represents -CH <sub>2</sub> -, -O- or -NH-,  |
| 10 | R <sup>2</sup>                                     | represents a hydrogen atom or an alkyl residue saturated or unsaturated once or several times and comprising from 1 to 50 carbon atoms, preferably 1 to 20 carbon atoms,   |
| 15 | R <sup>3</sup> , R <sup>4</sup> and R <sup>5</sup> | each represent, independently of each other, a hydrogen atom or an acyl-CO-R <sup>6</sup> residue in which R <sup>6</sup> represents an alkyl residue having from 1 to 10 carbon atoms,  |
| 20 | R <sup>7</sup>                                     | represents a hydrogen atom, a C <sub>1</sub> -C <sub>7</sub> alkyl, hydroxymethyl, 1-hydroxyethyl, mercaptomethyl, 2-(methylthio)ethyl, 3-aminopropyl, 3-ureidopropyl, 3-guanidylpropyl, 4-aminobutyl, carboxymethyl, carbamoylmethyl, 2-carboxyethyl, 2-carbamoylethyl, benzyl, 4-hydroxybenzyl, 3-indolylmethyl or 4-imidazolylmethyl group, |
| 25 | R <sup>8</sup>                                     | represents a hydrogen atom or a methyl group, and  |
| 30 | R <sup>9</sup>                                     | represents a hydrogen atom, an acetyl, benzoyl, trichloroacetyl, trifluoroacetyl, methoxycarbonyl, t-butyloxycarbonyl or benzyloxycarbonyl group, and  |

$R^7$  and  $R^8$  may, when they are taken together, represent a  $-CH_2-CH_2-CH_2-$  group.

- 5 (c) The use of an immunogenic agent derived from *Helicobacter* and of at least one compound selected from the compounds (i) to (iii) cited above, in the manufacture of a pharmaceutical composition capable of inducing a T helper 1 (Th1) type immune response against *Helicobacter*; and

10 (d) A method for preventing or treating an infection promoted by a microorganism capable of infecting the gastroduodenal mucous membrane of a mammal, e.g. a *Helicobacter* infection, according to which there is administered to the mammal by the systemic route, in one or more applications, a composition containing at least one immunogenic agent derived from the said microorganism, e.g. from *Helicobacter*, and at least one compound capable of promoting the induction of a T helper 1 (Th1) type immune response against e.g. *Helicobacter*.

15 (e) A method for preventing or treating an infection promoted by a microorganism capable of infecting the gastroduodenal mucous membrane of a mammal, e.g. a *Helicobacter* infection, according to which there is administered to the mammal, in one or more applications, a composition containing at least one immunogenic agent derived from the said microorganism, e.g. from *Helicobacter*, and at least one compound selected from the compounds (i) to (iii) cited above, and by which a Th1-type immune response is induced against e.g. *Helicobacter*.

20

25

30

35 The induction of a useful Th1 response can be demonstrated for the purposes of the present invention by estimating the relative level of the Th1 response relative to the Th2 response, by comparing, for

example, the IgG2a and IgG1 levels induced in mice against *Helicobacter*, which are respectively indicative of the coming into play of the Th1 and Th2 responses. Indeed, the Th1 response which is sought is generally 5 accompanied by a Th2 response. However, it is considered that the Th2 response should not be significantly predominant relative to the Th1 response. The IgG2a and IgG1 levels induced in mice can be assessed conventionally using an ELISA test, provided 10 that the tests used for each of the two subisotypes are of the same sensitivity and, in particular, that the anti-IgG2a and anti-IgG1 antibodies are of the same affinity.

The quantities of IgG2a and IgG1 may be 15 measured in particular using an ELISA test which is identical or similar to that described below. The wells of a polycarbonate ELISA plate are coated with 100 µl of a bacterial extract from *Helicobacter*, e.g. *H. pylori*, at about 10 µg/ml in carbonate buffer. The 20 ELISA plate is incubated for 2 hours at 37°C and then overnight at 4°C. The plate is washed with PBS buffer (phosphate buffer saline) containing 0.05% Tween 20 (PBS/Tween buffer). The wells are saturated with 250 µl of PBS containing 1% bovine serum albumin in order to 25 prevent nonspecific binding of the antibodies. After incubating for one hour at 37°C, the plate is washed with PBS/Tween buffer. The antiserum collected from mice, a number of days after the latter have received 30 the composition intended to induce a Th1-type immune response against *Helicobacter*, is serially diluted in PBS/Tween buffer. 100 µl of the dilutions are added to the wells. The plate is incubated for 90 minutes at 37°C, washed and evaluated according to standard 35 procedures. For example, a goat antibody to mouse IgG2a or IgG1, coupled to an enzyme such as peroxidase, is used. The incubation in the presence of this antibody is continued for 90 minutes at 37°C. The plate is washed and then the reaction is developed with the

CONFIDENTIAL

appropriate substrate (for example O-phenyldiamine dihydrochloride when the enzyme used is peroxidase). The reaction is evaluated by colorimetry (by measuring the absorbance by spectrophotometry). The IgG2a or IgG1  
5 titre of the antiserum corresponds to the reciprocal of the dilution giving an absorbance of 1.5 at 490 nm.

The induction of a useful Th1 response for the purposes of the present invention is marked by a ratio of the ELISA IgG2a : IgG1 titres in mice which should  
10 be greater than 1/100, 1/50 or 1/20, advantageously greater than 1/10, preferably greater than 1/3, most preferably greater than 1/2, 5 or 10. When this ratio is around 1, the Th1/Th2 response is said to be mixed or balanced. When the ratio is greater than or equal to  
15 5, the Th1 response is then said to be preponderant.

The production of a Th1 (or Th2) response in mice is predictive of a Th1 (or Th2) response in man. Although it is easier to evaluate the type of response in mice, it can also be done in man by measuring the  
20 levels of cytokines specific for the Th1 response on the one hand and, on the other hand, for the Th2 response, which are subsequently induced. The Th1 and Th2 responses can be evaluated directly in man relative to each other on the basis of the levels of cytokines specific for the two types of response (see above) e.g.  
25 on the basis of the IFN- $\gamma$ /IL-4 ratio.

Alternatively, if the assay method described above is used, it is possible to predict that the ELISA titre which reflects the quantity of IgG2a should be  
30 equal to or greater than 10,000, preferably equal to or greater than 100,000, in a particularly preferred manner equal to or greater than 1,000,000; this then means that the Th1 response is significant.

The mammal for which the pharmaceutical  
35 composition or the method is intended is advantageously a primate, preferably a human.

Saponins useful for the purposes of the present invention are described in particular in US Patent No.

5,057,540 with reference not to their structures but to the fractions in which they are present after fractionation of an aqueous extract of *Quillaja saponaria Molina* bark by high-performance liquid chromatography (HPLC) and low-pressure chromatography on silica. In particular, the fractions QA-7, QA-17, QA-18 and QA-21 also called QS-21 may be mentioned. The use of the latter is particularly advantageous. QS-21 is known to be an adjuvant which promotes the induction 10 of a predominantly Th1-type immune response. The adjuvant is then said to be of the Th1 type.

Useful cationic lipids for the purposes of the present invention are in particular described in US Patent No. 5,283,185. By way of example, there may be 15 mentioned cholesteryl-3 $\beta$ -carboxylamidoethylenetri-methylammonium iodide, 1-dimethylamino-3-trimethyl-ammonio-DL-2-propylcholesterylcarboxylate iodide, cholesteryl-3 $\beta$ -carboxyamidoethyleneamine iodide, cholesteryl-3 $\beta$ -oxysuccinamidoethylenetrimethylammonium 20 iodide, 1-dimethylamino-3-trimethylammonio-DL-2-propyl-cholesteryl-3 $\beta$ -oxysuccinate iodide, 2-[ (2-trimethyl-ammonio)ethylmethylamino]ethylcholesteryl-3 $\beta$ -oxy-succinate iodide, 3 $\beta$ -[N-(polyethyleneimine)carbamoyl]-cholesterol and 3 $\beta$ -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-chol) or a salt of the 25 latter. DC-chol (or its salt form) is known to be an adjuvant which promotes the induction of a Th1/Th2 type mixed balanced response. The adjuvant is then said to be of the Th1/Th2 or Th1 + Th2 type.

These cationic lipids may be used in dispersion 30 or alternatively made in the form of liposomes. Liposomes may be made as described in US Patent No. 5,283,185, by combining cationic lipids with a neutral phospholipid, e.g. phosphatidylcholine or phosphatidyl-ethanolamine.

Useful glycolipopeptides for the purposes of the present invention are in particular described in US Patent No. 4,855,283 and EP 206,037. They are in

particular glycolipids of general formula (I) in which a sugar residue is a 2-amino-2-deoxy-D-glucose or 2-amino-2-deoxy-D-galactose residue. The 2-amino group of the amino sugar may be linked to glycine, sarcosine, 5 hippuric acid, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, ornithine, citrulline, arginine, aspartic acid, asparagine, glutamic acid, glutamine, phenylalanine, tyrosine, proline, tryptophan or histidine in the D or L form, 10 with aminocarboxylic acids such as  $\alpha$ -aminobutyric acid,  $\alpha$ -aminovaleric acid,  $\alpha$ -aminocaproic acid or  $\alpha$ -aminoheptanoic acid in the D form or in the L form.

More particularly, the following glycolipoproteptides may be mentioned:

- 15 N-(2-glycinamido-2-deoxy- $\beta$ -D-glucopyranosyl)-N-dodecyldodecanoylamide,  
N-(2-glycinamido-2-deoxy- $\beta$ -D-glucopyranosyl)-N-dodecylactadecanoylamide,  
N-(2-glycinamido-2-deoxy- $\beta$ -D-glucopyranosyl)-N-tetra-  
20 decylidodecanoylamide,  
N-(2-L-alaninamido-2-deoxy- $\beta$ -D-glucopyranosyl)-  
N-dodecyldodecanoylamide,  
N-(2-D-alaninamido-2-deoxy- $\beta$ -D-glucopyranosyl)-  
N-dodecylactadecanoylamide,  
25 N-(2-L-phenylalaninamido-2-deoxy- $\beta$ -D-glucopyranosyl)-  
N-dodecylactadecanoylamide,  
N-(2-L-valinamido-2-deoxy- $\beta$ -D-glucopyranosyl)-N-octa-  
decylidodecanoylamide,  
N-(2-L-valinamido-2-deoxy- $\beta$ -D-glucopyranosyl)-N-octa-  
30 decyltetradecanoylamide,  
N-(2-L-leucinamido-2-deoxy- $\beta$ -D-glucopyranosyl)-  
N-dodecyldodecanoylamide,  
N-(2-L-leucinamido-2-deoxy- $\beta$ -D-glucopyranosyl)-N-octa-  
decylidodecanoylamide (Bay R1005), and  
35 N-(2-sarcosinamido-2-deoxy- $\beta$ -D-glucopyranosyl)-N-octa-  
decylidodecanoylamide.

A composition according to the invention may contain one or more compounds cited above. According to

an advantageous embodiment, two compounds are used; (a) one being selected from saponins purified from an extract of *Quillaja saponaria* and (b) the other being selected (i) either from cationic lipids or a salt of the latter, the said lipids being weak inhibitors of protein kinase C and having a structure which includes a lipophilic group derived from cholesterol, a bonding group selected from carboxyamides and carbamoyls, a spacer arm consisting of a branched or unbranched linear alkyl chain of 1 to 20 carbon atoms, and a cationic amine group selected from primary, secondary, tertiary and quaternary amines, (ii) or from glycolipeptides of formula (I). By way of example, the mixtures QS21 + DC-Chol and QS-21 + Bay R1005 may be mentioned.

Other adjuvants capable of promoting a Th1-type immune response (that is to say Th1 or Th1/Th2 type adjuvants) exist in the state of the art from which persons skilled in the art are capable of selecting the one which best corresponds to their needs. As a guide, there may be mentioned in particular liposomes; ISCOMS; microspheres; protein chochleates; vesicles consisting of nonionic surfactants; cationic amphiphilic dispersions in water; oil/water emulsions; muramidylpeptide (MDP) and its derivatives such as glucosyl muramidylpeptide (GMDP), threonyl-MDP, murametide and murapalmitin; as well as various other compounds such as monophosphoryl-lipid A (MPLA) major lipopolysaccharide from the wall of a bacterium, for example of *E. coli*, *Salmonella minnesota*, *Salmonella typhimurium* or *Shigella flexneri*; algan-glucan; gamma-inulin; calcitriol and loxoribine.

Useful liposomes for the purposes of the present invention may be selected in particular from pH-sensitive liposomes such as those formed by mixing cholesterol hemisuccinate (CHEMS) and dioleyl phosphatidyl ethanolamine (DOPE); liposomes containing cationic lipids recognized for their fusiogenic

properties, such as 3-beta-(N-(N',N'-dimethylamino-ethane)carbamoyl)cholesterol (DC-chol) and its equivalents which are described in US Patent No. 5,283,185 and WO 96/14831, dimethyldioctadecylammonium bromide (DDAB) and the BAY compounds described in EP 91645 and EP 206 037, for example Bay R1005 (N-(2-deoxy-2-L-leucylamino-beta-D-glucopyranosyl)-N-octa-decyldodecanoyleamide acetate; and liposomes containing MTP-PE, a lipophilic derivative of MDP (muramidyl dipeptide). These liposomes are useful for adding as adjuvant to all the immunogenic agents cited.

Useful ISCOMs for the purposes of the present invention may be selected in particular from those compounds of QuilA or of QS-21 combined with cholesterol and optionally also with a phospholipid such as phosphatidylcholine. These are particularly advantageous for the formulation of the lipid-containing antigens.

Useful microspheres for the purposes of the present invention may be formed in particular from compounds such as polylactide-co-glycolide (PLAGA), alginate, chitosan, polyphosphazene and numerous other polymers.

Useful protein cholesterolates for the purposes of  
the present invention may be selected in particular  
from those formed from cholesterol and optionally an  
additional phospholipid such as phosphatidylcholine.  
These are especially advantageous for the formulation  
of the lipid-containing antigens.

30 Useful vesicles consisting of nonionic surfactants for the purposes of the present invention may be in particular formed by a mixture of 1-mono-palmitoyl glycerol, cholesterol and dicetylphosphate. They are an alternative to the conventional liposomes  
35 and may be used for the formulation of all the immunogenic agents cited.

Useful oil/water emulsions for the purposes of the present invention may be selected in particular

from MF59 (Biocine-Chiron), SAF1 (Syntex) and the montanides ISA51 and ISA720 (Seppic).

The immunogenic agent derived from *Helicobacter* is advantageously selected from a preparation of 5 inactivated *Helicobacter* bacteria, a *Helicobacter* cell lysate, a peptide and a polypeptide from *Helicobacter* in purified form.

For the purposes of the present invention, a preparation of inactivated bacteria may be obtained 10 according to conventional methods well known to a person skilled in the art. Likewise for a bacterial lysate. A dose of inactivated bacteria or of cell lysate, appropriate for prophylactic or therapeutic purposes, can be determined by persons skilled in the 15 art and depends on a number of factors such as the individual for whom the vaccine is intended, e.g. age, the antigen itself, the route and mode of administration, the presence/absence or the type of adjuvant, as can be determined by persons skilled in 20 the art. In general, it is indicated that an appropriate dose is from about 50 µg to 1 mg to about 1 mg of lysate.

A peptide or a polypeptide derived from *Helicobacter* may be purified from *Helicobacter* or 25 obtained by genetic engineering techniques or alternatively by chemical synthesis. The latter process is advantageous in the case of peptides. "Peptide" is any amino acid chain whose size is less than about 50 amino acids. When the size is greater, the term 30 "polypeptide", which is also interchangeable with the term "protein", is used. A useful peptide or polypeptide for the purposes of the present invention may be identical or similar to that which exists under natural conditions. It is similar in that it is capable 35 of inducing an immune response of the same type but it may comprise certain structural variations such as, for example, a mutation, the addition of a residue of a

lipid nature or alternatively it may be in fusion polypeptide or peptide form.

An appropriate dose of peptide or polypeptide for prophylactic or therapeutic purposes can be  
5 determined by persons skilled in the art and depends on a number of factors such as the individual for whom the vaccine is intended, e.g. age, the antigen itself, the route and mode of administration, the presence/absence or the type of adjuvant, as can be determined by  
10 persons skilled in the art. In general, it is indicated that an appropriate dose is from about 10 µg to about 1 mg, preferably at about 100 µg.

The immunogenic agent derived from *Helicobacter* may be any polypeptide from *Helicobacter*, e.g. *H.  
15 pylori*. This may be in particular a polypeptide present in the cytoplasm, a polypeptide of the inner or outer membrane or a polypeptide secreted in the external medium. Numerous polypeptides from *Helicobacter* have already been described in the literature, either with  
20 reference to their amino acid sequence deduced from the sequence of the cloned or identified corresponding gene, or with reference to a purification process which makes it possible to obtain them in a form isolated from the rest of their natural environment. As a guide,  
25 the following documents may be mentioned in particular: WO 94/26901 and WO 96/34624 (HspA), WO 94/09023 (CagA), WO 96/38475 (HpaA), WO 93/181150 (cytotoxine), WO 95/27506 and Hazell et al., J. Gen. Microbiol. (1991)  
137: 57 (catalase), FR 2 724 936 (membrane receptor for  
30 human lactoferrin), WO 96/41880 (AlpA), EP 752 473 (FibA) and O'Toole et al., J. Bact. (1991) 173: 505 (TsaA). Other polypeptides are also described in WO 96/40893, WO 96/33274, WO 96/25430 and WO 96/33220. A useful polypeptide for the purposes of the present  
35 invention may be identical or similar to one of those cited as a reference insofar as it is capable of promoting an immune response against *Helicobacter*. In order to meet this last condition, the immunogenic

agent may also be a peptide derived from a polypeptide cited as a reference.

Advantageously, a polypeptide selected from the UreA and UreB subunits of *Helicobacter* urease is used  
5 (see WO 90/4030). Preferably, both are used, combined in urease apoenzyme form or alternatively in multimeric form (see WO 96/33732).

A useful pharmaceutical composition for the purposes of the present invention may contain a single  
10 immunogenic agent or several. For example, an advantageous composition may comprise UreA and UreB, e.g. in apoenzyme form, as well as one or more other polypeptides selected in particular from those mentioned above.

15 A useful pharmaceutical composition for the purposes of the present invention may, in addition, contain compounds other than the immunogenic agent itself and the Th1 or Th1/Th2 type adjuvant, the nature of these compounds depending to some extent on the  
20 nature of the immunogenic agent, inactivated bacteria, cell lysate, peptide or polypeptide. For example, a composition may also comprise an adjuvant capable of promoting the induction of a Th2-type immune response, e.g. an aluminium compound such as aluminium hydroxide,  
25 aluminium phosphate or aluminium hydroxyphosphate. This may be advantageous insofar as the useful adjuvant for the purposes of the present invention is a Th1-type adjuvant such as QS-21.

The therapeutic or prophylactic efficacy of a  
30 method or of a use according to the invention may be evaluated according to standard methods, e.g. by measuring the induction of an immune response or the induction of a therapeutic or protective immunity using e.g. the mouse/*H. felis* model and the procedures  
35 described in Lee et al., Eur. J. Gastroenterology & Hepatology (1995) 7: 303 or Lee et al., J. Infect. Dis. (1995) 172: 161. Persons skilled in the art will realize that *H. felis* can be replaced in the mouse

model by another *Helicobacter* species. For example, the efficacy of an immunogenic agent derived from *H. pylori* is preferably evaluated in a mouse model using an *H. pylori* strain adapted to mice. The efficacy may be determined by comparing the level of infection in the gastric tissue (by measuring the urease activity, the bacterial load or the condition of the gastritis) with that in a control group. A therapeutic effect or a protective effect exists when the infection is reduced compared with the control group.

A useful pharmaceutical composition for the purposes of the present invention may be manufactured in a conventional manner. In particular, it may be formulated with a pharmaceutically acceptable carrier or diluent, e.g. water or a saline solution. In general, the diluent or carrier may be selected according to the mode and route of administration and according to standard pharmaceutical practices. Appropriate carriers or diluents as well as what is essential for the preparation of a pharmaceutical composition are described in *Remington's Pharmaceutical Sciences*, a standard reference book in this field.

The methods according to the invention as well as the compositions useful for these purposes may be used to treat or prevent i.a. *Helicobacter* infections and consequently the gastroduodenal diseases associated with these infections, including acute, chronic or atrophic gastritis, peptic ulcers, e.g. gastric or duodenal ulcers.

30 A pharmaceutical composition according to the invention may be administered conventionally, in particular by the mucosal route, e.g. by the ocular, oral, e.g. buccal or gastric, pulmonary, intestinal, rectal, vaginal or urinary route or by the systemic, in particular parenteral, e.g. intravenous, intramuscular, intradermal, intraepidermal and subcutaneous, route. Preferably, the parenteral route is used. When the parenteral route is used, a site of administration

situated under the diaphragm of an individual is preferably chosen. The dorsolumbar region constitutes, for example, an appropriate site of administration, in particular for the intraepidermal, intramuscular, 5 intradermal and subcutaneous routes, these latter routes being chosen in preference to the intravenous route.

To obtain a protective or therapeutic effect, the operation which consists in administering a useful 10 pharmaceutical composition for the purposes of the present invention may be repeated once or several times, preferably at least twice, leaving a certain time interval between each administration, which interval is of the order of a week or a month. Its 15 precise determination is within the capability of persons skilled in the art and may vary according to various factors such as the nature of the immunogenic agent, the age of the individual and the like.

According to a specific mode, the vaccination 20 procedure is carried out using the same route of administration during the first immunization and the boosters. In this particular case, the administration is said to be for example of the strict systemic type.

"A method in which the administration of the 25 immunogenic agent is carried out by the strict systemic route" is defined as a method not using a route of administration other than the systemic route. For example, a method in which the immunogenic agent is administered by the systemic route and by the mucosal 30 route does not correspond to the definition given above. In other words, "a method in which the administration of the immunogenic agent is carried out by the strict systemic route" should be understood to mean a method in which the immunogenic agent is 35 administered by the systemic route excluding any other route, in particular the mucosal route.

By way of a nonlimiting illustration, there may be mentioned a vaccination scheme which consists in

administering the urease apoenzyme in combination with QS-21, DC-chol or one of their equivalents, three times by the subcutaneous route, in the dorsolumbar region with an interval of two to four weeks between each 5 administration.

- It is also possible to predict that the administration of a pharmaceutical composition according to the present invention may be a single step forming part of a more elaborate vaccination procedure.
- 10 For example, a pharmaceutical composition according to the present invention may be preceded or followed by the administration of a pharmaceutical composition containing an immunogenic agent derived from *Helicobacter* chosen independently from those stated
- 15 above or among others such as a vaccinal vector or a DNA molecule, but not containing QS-21, DC-chol or one of their equivalents, it being possible for the latter to then be replaced by a completely different adjuvant, it being possible for the two compositions to be
- 20 administered by identical or different routes.

By way of a nonlimiting illustration, the following procedures may be mentioned:

- A first immunization by the systemic route, with the urease apoenzyme in the presence of QS-21,

25 followed by two boosters with the urease apoenzyme in the presence of QS-21 or LT by the mucosal route; and

  - A first immunization by the systemic route, with a poxvirus encoding UreA and UreB followed by two boosters with the urease apoenzyme in the presence of

30 QS-21, by the systemic or mucosal route.

Immunogenic agents, other than those described above and which are capable of being used in a multistep vaccination procedure comprising a step of administration using a useful medicament for the 35 purposes of the present invention or a composition according to the present invention, may be selected from a polynucleotide molecule, in particular a DNA molecule comprising a sequence encoding a peptide or a

polypeptide from *Helicobacter* placed under the control of the elements necessary for its expression in a mammalian cell; or alternatively a vaccinal vector comprising a sequence encoding a peptide or a  
5 polypeptide from *Helicobacter* placed under the control of the elements necessary for its expression in a mammalian cell (if this is a viral vector) or in a prokaryote (if this is a bacterial vector).

The DNA molecule may advantageously be a  
10 plasmid which is incapable both of replicating and of substantially integrating into the genome of a mammal. The abovementioned coding sequence is placed under the control of a promoter allowing expression in a mammalian cell. This promoter may be ubiquitous or  
15 specific for a tissue. Among the ubiquitous promoters, there may be mentioned the cytomegalovirus early promoter (described in US Patent No. 4,168,062) and the Rous sarcoma virus promoter (described in Norton & Coffin, Molec. Cell. Biol. (1985) 5: 281). The desmin  
20 promoter (Li et al., Gene (1989) 78: 244443; Li & Paulin, J. Biol. Chem. (1993) 268: 10403) which is a selective promoter allows expression in muscle cells and also in skin cells. A promoter specific for the muscle cells is for example the promoter of the myosin  
25 or dystrophin gene. Plasmid vectors which can be used for the purposes of the present invention are described i.a. in WO 94/21797 and Hartikka et al., Human Gene Therapy (1996) 7: 1205.

In a useful pharmaceutical composition for the  
30 purposes of the present invention, the nucleotide molecule, e.g. the DNA molecule, may be formulated or otherwise. The choice of formulation is highly varied. The DNA may be simply diluted in a physiologically acceptable solution with or without carrier. When the latter is present, it may be isotonic or weakly hypertonic and may have a low ionic strength. For example, these conditions may be fulfilled by a sucrose solution, e.g. at 20%.

008267-7950000

Alternatively, the polynucleotide may be combined with agents which promote entry into the cell. This may be (i) a chemical agent which modifies cell permeability, such as bupivacaine (see for example WO 5 94/16737) or (ii) an agent which is combined with the polynucleotide and which acts as a vehicle facilitating the transport of the polynucleotide. The latter may be in particular cationic polymers, e.g. polylysine or a polyamine, e.g. derivatives of spermine (see WO 10 93/18759). This may also be fusogenic peptides, e.g. GALA or Gramicidin S (see WO 93/19768) or alternatively peptides derived from viral fusion proteins.

This may also be anionic or cationic lipids. The anionic or neutral lipids have been known for a long time to be capable of serving as transporting agents, for example in the form of liposomes, for a large number of compounds including polynucleotides. A detailed description of these liposomes, of their constituents and of the processes for their manufacture 20 is for example provided by Liposomes: A Practical Approach, RPC New Ed., IRL press (1990).

The cationic lipids are also known and are commonly used as transporting agents for polynucleotides. There may be mentioned for example 25 Lipofectin™ also known by the name DOTMA (*N*-[1-(2,3-dioleyloxy) propyl]-*N,N,N*-trimethylammonium chloride), DOTAP (1,2-bis(oleyloxy)-3-(trimethylammonio)propane), DDAB (dimethyldioctadecylammonium bromide), DOGS (dioctadecylamidoglycyl spermine) and 30 cholesterol derivatives such as DC-chol (3-beta-(*N*-(*N*',*N*'-dimethylaminoethane)carbamoyl)cholesterol). A description of these lipids is provided by EP 187,702, WO 90/11092, US Patent No. 5,283,185, WO 91/15501, WO 95/26356 and US Patent No. 5,527,928. The cationic 35 lipids are preferably used with a neutral lipid such as DOPE (dioleylphosphatidylethanolamine) as is for example described in WO 90/11092.

Gold or tungsten microparticles may also be used as transporting agents, as described in WO 91/359, WO 93/17706 and Tang et al., Nature (1992) 356: 152. In this particular case, the polynucleotide is  
5 precipitated on the microparticles in the presence of calcium chloride and spermidine and then the whole is administered by a high-speed jet into the dermis or into the epidermis using an apparatus with no needle such as those described in US Patents No. 4,945,050 and  
10 No. 5,015,580 and WO 94/24243.

The quantity of DNA which may be used to vaccinate an individual depends on a number of factors such as for example the strength of the promoter used to express the antigen, the immunogenicity of the  
15 product expressed, the condition of the mammal for whom the administration is intended (e.g. the weight, age and general state of health), the mode of administration and the type of formulation. In general, an appropriate dose for prophylactic or therapeutic use  
20 in an adult of the human species is from about 1 µg to about 5 mg, preferably from about 10 µg to about 1 mg, most preferably from about 25 µg to about 500 µg.

Vaccinal vectors are among the immunogenic agents mentioned above. Adenoviruses and poxviruses in  
25 particular are among the vectors of viral origin. An example of a vector derived from an adenovirus as well as a method for constructing a vector capable of expressing a DNA molecule encoding a useful peptide or polypeptide for the purposes of the present invention  
30 are described in US Patent No. 4,920,209. Poxviruses which may be used likewise are for example the vaccinia and canarypox viruses. They are described respectively in US Patents No. 4,722,848 and 5,364,773 (see also e.g. Tartaglia et al., Virology (1992) 188: 217 and  
35 Taylor et al., Vaccine (1995) 13: 539). Poxviruses capable of expressing a useful peptide or polypeptide for the purposes of the present invention may be obtained by homologous recombination as described in

Kieny et al., *Nature* (1984) 312: 163, such that the DNA fragment encoding the peptide or polypeptide is placed under conditions appropriate for its expression in mammalian cells. A bacterial vector such as the bile 5 Calmette-Guérin bacillus may also be envisaged.

In general, the dose of a viral vector intended for prophylactic or therapeutic purposes may be from about  $1 \times 10^4$  to about  $1 \times 10^{11}$ , advantageously from about  $1 \times 10^7$  to about  $1 \times 10^{10}$ , preferably from about  $1 \times 10^7$  to about  $1 \times 10^9$  plaque forming units per kilogram. 10

Among the bacterial vectors, there may be mentioned *Shigella*, *Salmonella*, *Vibrio cholerae*, *Lactobacillus* and *Streptococcus*. Nontoxic mutant 15 strains of *Vibrio cholerae* which may be useful as live vaccine are described in Mekalanos et al., *Nature* (1983) 306: 551 and US Patent No. 4,882,278 (strain in which a substantial part of the region encoding each of the two alleles *ctxA* has been deleted so that no 20 functional toxin can be produced); WO 92/11354 (strain in which the *irgA* locus is inactivated by mutation; this mutation may be combined in the same strain with *ctxA* mutations); and WO 94/1533 (mutant obtained by deletion lacking functional *ctxA* and *attRS1* sequences). 25 These strains may be modified genetically in order to express heterologous antigens as described in WO 94/19482.

Attenuated strains of *Salmonella typhimurium*, genetically modified or otherwise for the recombinant 30 expression of heterologous antigens, as well as their use as vaccines are described in Nakayama et al., *BioTechnology* (1988) 6: 693 and WO 92/11361.

Other bacteria useful as vaccinal vectors are described in High et al., *EMBO* (1992) 11: 1991 and 35 Sizemore et al., *Science* (1995) 270: 299 (*Shigella flexneri*); Medaglini et al., *Proc. Natl. Acad. Sci. USA* (1995) 92: 6868 (*Streptococcus gordonii*); and Flynn J.L., *Cell. Mol. Biol.* (1994) 40 (suppl. I): 31, WO

88/6626, WO 90/0594, WO 91/13157, WO 92/1796 and WO 92/21376 (Calmette-Guérin bacillus).

In bacterial vectors, the DNA sequence encoding a peptide or polypeptide from *Helicobacter* may be 5 inserted into the bacterial genome or alternatively remain in the free state, carried by a plasmid.

Likewise, a DNA molecule or a vaccinal vector may comprise a sequence encoding any polypeptide or peptide described above.

10 A DNA molecule, preferably a viral vaccinal vector, may also comprise a sequence encoding a cytokine, for example a lymphokine such as interleukin-2 or -12, under the control of elements appropriate for expression in a mammalian cell. An alternative to this 15 option also consists in adding to a useful pharmaceutical composition for the purposes of the present invention comprising a DNA molecule or a vector, another molecule or viral vector encoding a cytokine.

20 In general, the subject of the invention is therefore also a pharmaceutical composition intended to treat or prevent a *Helicobacter* infection which comprises, for consecutive administration: (i) a first product containing (a) an immunogenic agent derived 25 from *Helicobacter* selected independently from a preparation of inactivated *Helicobacter* bacteria, a *Helicobacter* cell lysate, a peptide and a polypeptide from *Helicobacter* in purified form, and (b) a compound capable of promoting the induction of a Th1-type immune 30 response and (ii) a second product containing an immunogenic agent derived from *Helicobacter* selected independently from a preparation of inactivated *Helicobacter* bacteria, a *Helicobacter* cell lysate, a peptide and a polypeptide from *Helicobacter* in purified 35 form, a DNA molecule comprising a sequence encoding a peptide or a polypeptide from *Helicobacter* placed under the control of the elements necessary for its expression and a vaccinal vector comprising a sequence

encoding a peptide or a polypeptide from *Helicobacter* placed under the control of the elements necessary for its expression, preferably provided that when a first product contains a peptide or a polypeptide and a 5 second product contains a DNA molecule or a vaccinal vector, the said coding sequence of the DNA molecule or of the vaccinal vector encodes the peptide or polypeptide contained in the first product.

In the description above, reference was made 10 essentially to *Helicobacter* infections and to the means for combating them by way of prevention and prophylaxis. However, it should be understood that the principles and methods stated above can be applied *mutatis mutandis* to any other infection induced by any 15 microorganism whose seat is the stomach, the duodenum or the intestine.

It is specified, in addition, that all the documents published and cited in the present application are incorporated by reference.

20 The invention is illustrated below with reference to the following figures.

Figure 1 refers to Example 1 and presents the levels of urease activity after a challenge, measured 4 h after sacrificing mice which have received 3 times, 25 on D0, D28 and D56: (a) a urease preparation encapsulated at about 80% in DC-chol liposomes, in the dorsolumbar muscles; or (b) a urease preparation with cholera toxin adjuvant, by the intragastric route. Experiments (c) and (d) correspond respectively to the 30 positive and negative controls.

Figure 2 refers to Example 1 and presents the levels of urease activity after a challenge, measured 4 h after sacrificing mice having received 3 times, on D0, D28 and D56: (a) a urease preparation with cholera 35 toxin adjuvant, by the intragastric route or (b) a urease preparation with PCPP adjuvant, by the subcutaneous route in the left posterior sublumbar part; or (c) a urease preparation with QS-21 adjuvant,

by the subcutaneous route in the lower back. Experiments (c) and (d) correspond respectively to the positive and negative controls.

Figure 3 presents the quantities of serum immunoglobulins induced in monkeys subjected to the immunization procedures described in Example 2, and expressed as ELISA titre. A control group comprising 4 monkeys and three test groups are formed, each of the test groups comprising 8 monkeys; each test group is divided into two subgroups of 4 monkeys, one receiving only the inactivated *H. pylori* preparation (1, 2 and 3) and the other receiving the inactivated *H. pylori* preparation and recombinant urease (1u, 2u and 3u). Group 1 and 1u corresponds to the administration procedure [nasal + intragastric, 4 times]; group 2 and 2u corresponds to the administration procedure [intramuscular, 4 times]; group 1 and 1u corresponds to the administration procedure [nasal + intragastric, intramuscular, nasal + intragastric, intramuscular]. The ELISA titre is measured three times: a first time at D0 (white band), a second time at D42 (shaded band), a third time at D78 (black band).

Figure 4 presents the quantities of serum immunoglobulins induced in mice subjected to the immunization procedures described in Example 3, and expressed as ELISA titre. O indicates the ELISA IgG2a titre and ♦ indicates the ELISA IgG1 titre. Two control groups (positive and negative controls), four test groups (A1 to A4) as well as a reference group (LT) are formed, each of the groups comprising 10 mice. The measurements of the quantities of serum immunoglobulins are carried out for only 5 mice among the ten. The mice of the A1 to A4 groups received 10 µg doses of urease by the subcutaneous route in the left posterior sublumbar part, in the presence of QS-21 (A1), Bay R1005 (A2), DC-chol (A3) or PCPP (A4). The mice of the reference group received 40 µg doses of

urease by the oral route in the presence of *E. coli* heat-labile protein.

Figure 5 presents the levels of urease activity measured at the level of the stomachic mucous membrane, 5 at OD<sub>550</sub> 4 hours after the mice subjected to the immunization procedures described in Example 3 have been sacrificed. The groups are as described in Figure 4.

Figure 6 presents the levels of urease activity 10 measured at the level of the stomachic mucous membrane at OD<sub>550</sub> 24 hours after the mice subjected to the immunization procedures described in Example 3 have been sacrificed. The groups are as described in Figure 4.

15 Figure 7 presents the bacterial load measured at the level of the stomachic mucosal membrane after the mice subjected to the immunization procedures described in Example 3 have been sacrificed. The groups are as described in Figure 4.

20 Figures 8A and 8B present the urease activity (Fig. 6A) evaluated after 4 h (OD at 550 nm) with the Jatrox test (Procter & Gamble) and the bacterial load (Fig. 6B) in mice infected with *H. pylori* and then subjected to various treatments A-H [A : LT + urease by 25 the oral route; B : QS21 + urease, by the parenteral route, in the neck; C : QS21 + urease, by the parenteral route, in the lumbar region; D : QS21 alone by the subcutaneous route, in the lumbar region; E : Bay R1005 + urease, by the parenteral route, in the neck; F : Bay R1005 + urease, by the parenteral route, in the lumbar region; G : Bay R1005 alone, by the 30 subcutaneous route, in the lumbar region (control); H : saline solution by the subcutaneous route in the lumbar region (positive control)] I represents the 35 negative control.

**Example 1: Immunization studies in mice**

**1A- Materials and methods**

**5 Mice**

6/8-week old female Swiss mice were provided by Janvier (France). During the whole experiment, sterilized materials were used; the cages were protected by "isocaps"; the mice were fed with filtered water and irradiated food.

**Administration procedure**

During each experiment, the mice received 3 doses of the same product; each dose at 28-day intervals (days 0, 28 and 56). The administration of the product was carried out by the nasal route (up to 50 µl on waking mice), by the oral route (300 µl in 0.2 M NaHCO<sub>3</sub> by gastric gavage), or by the subcutaneous route (300 µl under the skin of the neck or under the skin on the left side of the lumbar region). In some cases, an intramuscular inoculation was carried out (50 µl) in the dorsolumbar muscles of anaesthetized mice. 10 µg of urease were administered by the nasal, subcutaneous or intramuscular route, and 40 µg by the oral route. As regards the inactivated bacterial preparation, 400 µg of cells were administered by the subcutaneous route or by the oral route.

**Antigens and adjuvants**

The *H. pylori* urease apoenzyme was expressed in *E. coli* and purified as has been described in Example 5 of WO 96/31235. In the remainder of the text, the simple term of urease is used to designate this apoenzyme.

DC-chol liposomes containing urease are prepared as follows: first of all, to obtain a dry lipid film containing 100 mg of DC-chol (R-Gene Therapeutics) and 100 mg of DOPC

(dioleylphosphatidylcholine) (Avanti Polar Lipids), these products are mixed in powdered form in about 5 ml of chloroform. The solution is allowed to evaporate under vacuum using a rotary evaporator. The film thus obtained on the walls of the container is dried under high vacuum for at least 4 h. In parallel, 20 mg of a urease lyophilisate and 100 mg of sucrose are diluted in 13.33 ml of 20 mM Hepes buffer pH 7.2. Ten ml of this preparation (which contains 1.5 mg of urease and 0.75% sucrose) is filtered on the 0.220 µm Millex filter and then used to rehydrate the lipid film. The suspension is stirred for 4 h and then either extruded (10 passes on a 0.2 µm polycarbonate membrane) or microfluidized (10 passes at a pressure of 500 kPa in a Microfluidics Co Y10 microfluidizer). In the liposome suspension thus obtained, the level of encapsulated urease is from 10 to 60%. This suspension is lyophilized after having adjusted the sucrose concentration to 5% (425 mg of sucrose are added per 10 ml). Before use, the lyophilisate is taken up in an appropriate volume of water or buffer and the suspension is purified on a discontinuous sucrose gradient (steps of 0, 30 and 60%) so as to obtain a preparation in which the quantity of encapsulated urease is greater than about 70% compared with the total quantity of urease.

The cholera toxin is used as mucosal adjuvant in an amount of 10 µg/dose of urease or of bacterial preparation.

The QS-21 (Cambridge Biosciences) is used as adjuvant in an amount of 15 µg/dose of urease.

The polyphosphazene (PCPP) (Virus Research Institute) is used as adjuvant in an amount of 100 µg/dose of urease.

35

#### Challenge

Two weeks after the second booster, the mice were subjected to a gastric gavage with 300 µl of a

suspension of a strain of *H. pylori* adapted to the mice, the strain ORV2002 ( $1 \times 10^7$  live bacteria in 200  $\mu$ l of PBS; OD<sub>550</sub> of about 0.5). One group which received no dose of antigen and which serves as control 5 is challenged likewise.

#### **Analysis of the challenge**

Four weeks after the challenge, the mice were sacrificed by breaking the cervical vertebrae. The 10 stomachs were removed in order to evaluate the urease activity and to make histological analyses. The urease activity was evaluated after 4 and 24 hours (OD at 550 nm) with the Jatrox test, Procter & Gamble) and after 24 hours the number of mice still negative (OD 15 less than 0.1) was noted.

#### **Measurement of the local antibody response by ELISPOT (salivary glands and stomach).**

The ELISPOTS were performed in accordance with 20 Mega et al., J. Immunol. (1992) 148: 2030. The plates were coated with an extract of *H. pylori* proteins at a concentration of 50  $\mu$ g/ml.

To test the antibody response at the level of the stomach, we modified the method as follows: half of 25 the stomach was cut into 1-mm<sup>2</sup> pieces with an automatic apparatus for cutting human tissues (McIllwain Laboratories, Gilford, UK) and the digestion carried out with Dispase (2 mg/ml, Boeringher Mannheim) in 2 ml of a modified Joklik solution to which 10% horse serum 30 (Gibco), glutamine and antibiotics were added. Four half-hour digestions were performed at 37°C with gentle mixing. The cells thus digested were filtered after each step using 70  $\mu$ m filters (Falcon), and then washed 3 times in a solution of RPMI 1640 (Gibco) supplemented 35 with 5% foetal calf serum (FCS), and incubated in the same solution for at least 4 hours in plates covered with nitrocellulose (Millipore) (100  $\mu$ l/well, 4 wells). Between 1 and 3  $\times$  10<sup>5</sup> cells are obtained per half

stomach (the cells of large size and the macrophages were not counted).

The biotinylated IgA and the streptavidin-biotinylated peroxidase complex were obtained from 5 Amersham. The spots were revealed under the action of the AEC substrate (Sigma) and as soon as the plates are dry, they were counted under a microscope (magnification  $\times 16$  or  $\times 40$ ). The mean values corresponding to the number of IgA spots in four wells 10 were calculated and expressed as the number of spots/ $10^6$  cells.

#### **Analysis of the response by ELISA**

The analyses by ELISA were performed in 15 accordance with the standard procedure (the biotinylated conjugates and the streptavidin-peroxidase were obtained from Amersham and the OPD (O-phenyldiamine dihydrochloride) substrate from Sigma). The plates were coated with *H. pylori* extracts (5  $\mu\text{g}/\text{ml}$ ) in 20 carbonate buffer. A control serum from mice directed against the *H. pylori* extract was introduced in each experiment. The titre corresponds to the reciprocal of the dilution giving an OD of 1.5 at 490 nm.

#### **25 1B- Results**

The results are presented in Figures 1 and 2 described above and by the following comments:

Before any comments on the subject of Figures 1 and 2, it should be noted that these figures present 30 the results obtained with the antigen used with the cholera toxin adjuvant and administered by the intragastric route. This experiment is termed standard reference experiment since the prior art CT/IG combination is that which gives the best results up 35 until now.

Figure 1 shows that a urease preparation encapsulated into DC-chol liposomes gives results as

good as those obtained in the standard reference experiment.

Furthermore, reference can be made to experiments (a) to (d) whose results in terms of urease activity 4 h after the mice have been sacrificed are reported in Figure 1 and it is indicated that the number of mice which are still negative for the urease activity 24 h after having been sacrificed is respectively (a) 5/10, (b) 4/10, (c) 0/10 and (d) 10/10. This is in agreement with what was previously concluded in the paragraph; namely that experiment (a) leads to results similar to those obtained during the standard reference experiment.

Figure 2 shows that a urease preparation with QS-21 adjuvant gives results as good as those obtained in the standard reference experiment. Furthermore, this figure shows that the results which are obtained using PCPP as adjuvant are a lot less satisfactory than those obtained with QS-21. This can be explained since PCPP induces, preferentially with urease, a Th2-type response whereas QS-21 with urease induces a Th1/Th2 balanced response, as demonstrated in the table below.

Furthermore, reference can be made to experiments (a) to (e) whose results in terms of urease activity 4 h after the mice have been sacrificed are reported in Figure 2 and it is indicated that the number of mice which are still negative for the urease activity 24 h after having been sacrificed is respectively (a) 1/8, (b) 0/8, (c) 5/8, (d) 0/8 and (e) 10/10. This is in agreement with what was previously concluded in the paragraph, namely that experiment (c) leads to results similar to those obtained during the standard reference experiment.

The table below presents the quantities of serum IgA, IgG1 and IgG2a induced during experiments whose results in terms of urease activity are reported in Figures 1 and 2 as well as the number of mice whose urease activity is characterized by an OD of less than

0.1 after 4 and 24 h after sacrifice. The quantities of IgA, IgG1 and IgG2a are expressed as ELISA titre.

|            | urease<br>CT IG | urease<br>DC-chol SC | urease<br>PCPP SC | urease<br>QS21 SC |
|------------|-----------------|----------------------|-------------------|-------------------|
| IgA        | 45              | 0                    | 58                | 1                 |
| IgG1       | 65700           | 620000               | 2930520           | 2970399           |
| IgG2a      | 20200           | 321000               | 26200             | 1136095           |
| OD<0.14 h  | 5/10            | 5/10                 | 0/8               | 6/8               |
| OD<0.124 h | 4/10            | 5/10                 | 0/8               | 5/8               |

5           The results presented in the table above show  
that when the subcutaneous route is used (as well as an  
adjuvant appropriate for this route), the serum  
antibody level is high, which is not the case after  
using the intragastric route (and adjuvant which is  
10          appropriate for this route). Furthermore, these results  
show that when DC-chol or QS-21 is used, a high IgG2a  
level is obtained comparable to the IgG1 level in order  
of magnitude. This indicates that these adjuvants have  
the capacity to induce not only a Th2 response, but  
15          also a Th1 response. On the other hand, when PCPP is  
used, the IgG2a level obtained is substantially lower  
than the IgG1 level. It can be concluded that the  
latter adjuvant induces essentially a Th2 response and  
cannot therefore be a useful adjuvant for the purposes  
20          of the present invention.

**Example 2: Immunization studies in monkeys**

**2A- Materials and methods**

25

**Monkeys**

30          Twenty eight 2-year old monkeys (*Macaca fascicularis*) obtained from Mauritius were used in this study. Before subjecting the monkeys to the various immunization procedures described below, a biopsy showed that most of them were chronically infected with

organisms similar to *Gastrospirillum hominis* (GHLO) or *H. heilmanii*.

**Administration procedures**

- 5 Since nearly all the monkeys were infected with GHLOs, it was decided to test the efficacy of the various procedures in therapy. Three procedures were used, as summarized in the table below:

| Group    | D0      | D21     | D42     | D63     |
|----------|---------|---------|---------|---------|
| 1 and 1u | IN + IG | IN + IG | IN + IG | IN + IG |
| 2 and 2u | IM      | IM      | IM      | IM      |
| 3 and 3u | IM      | IN + IG | IM      | IN + IG |

10

It is specified that the administration by the intramuscular route was carried out in the dorsolumbar muscles.

15 **Antigens and adjuvants**

Since there is a cross-reactivity between the GPLOs and *H. pylori*, it was chosen to use a preparation of inactivated *H. pylori* bacteria, as described in Example 1A, alone or in combination with recombinant urease prepared according to the method referenced in Example 1A.

20 The *E. coli* heat-labile toxin (LT) (Sigma) or the B subunit of the cholera toxin (CTB) (Pasteur Mérieux sérum & vaccins) was used as mucosal adjuvant whereas DC-chol was used as parenteral adjuvant. DC-chol powder is simply rehydrated with an antigen preparation.

The doses used are as follows:

| Route | Microorganisms | Urease | DC-chol | LT    | CTB   |
|-------|----------------|--------|---------|-------|-------|
| IG    | 400 µg         | 2.5 mg | -       | 25 µg | -     |
| IN    | 400 µg         | 400 µg | -       | 25 ng | 25 µg |
| IM    | 400 µg         | 100 µg | 400 µg  | -     | -     |

30

**Biopsies, urease test and bacteriological/histological study**

A biopsy was performed on each of the monkeys before and after immunization (one month after the 5 third booster). Using the biopsies, a urease test and a histological study were performed.

The urease activity is evaluated using the Jatrox kit (Procter & Gamble). The level of this activity is estimated as follows, in a decreasing 10 manner: level 3, pink colour appearing during the first 10 minutes; level 2, pink colour appearing between 10 and 30 minutes after the addition of the reagents; level 1, pink colour appearing between 30 min and 4 h and level 0, weak or no colour after 4 h.

15 The histological studies were performed using biopsies fixed in formalin and the bacterial load was quantified as follows: absence of bacteria (0); a few bacteria of the *Helicobacter* type (0.5); fairly numerous bacteria (1); numerous bacteria (2); highly 20 numerous bacteria (3). A difference of one level (for example from 1 to 2) corresponds to a number of bacteria 5 times greater.

**Analysis of the response by the ELISA test**

25 An ELISA test is carried out as described in Example 1A.

**1B- Results**

The table below relates to the bacterial load 30 which, before and after immunization, is assessed using two tests: (i) by evaluating the urease activity and (ii) by carrying out a histological study. The results relating thereto are presented in columns 3 to 6. The last three columns indicate for each group (control, 1, 35 2 or 3) the number of monkeys for which the bacterial load remains unchanged after immunization ( $\rightarrow$ ) according to the two tests; or appears lower ( $\blacktriangleleft$ ) or increased ( $\nearrow$ ) in at least one of the two tests, the

other test indicating a stationary bacterial load. When the results of the two tests show a similar variation, the upwards or downwards arrow is double.

| Monkeys | Group | Urease activity     |                    | Histology           |                    | Variation |     |        |
|---------|-------|---------------------|--------------------|---------------------|--------------------|-----------|-----|--------|
|         |       | before immunization | after immunization | before immunization | after immunization | ↘         | ↗   | ↗      |
| H 282   | C     | 2-2                 | 3-2                | 2                   | 3-2                |           |     |        |
| J 005   | C     | 2-2                 | 2-1                | 2                   | 1-0                | 1/4       | 1/4 | 2/4    |
| J 852   | C     | 0-0                 | 2-0                | 0                   | 1-1                |           |     | (2/4↗) |
| J 476   | C     | 0-0                 | 2-0                | 0                   | 1-1                |           |     |        |
| H 799   | 1     | 2-2                 | 2-2                | 2                   | 2-2                |           |     |        |
| J 845   | 1     | 2-2                 | 3-2                | 2                   | 2-1                |           |     |        |
| J 205   | 1     | 1-1                 | 2-2                | 0                   | 1                  |           |     |        |
| J 328   | 1     | 2-2                 | 1-2                | 3                   | 3-2                | 1/8       | 5/8 | 2/8    |
| J 197   | lu    | 2-2                 | 3-2                | 2                   | 3                  |           |     | (1/8↗) |
| H 025   | lu    | 2-2                 | 2-2                | 1                   | 1-1                |           |     |        |
| G 460   | lu    | 2-2                 | 3-2                | 3                   | 2-3                |           |     |        |
| J 607   | lu    | 2-2                 | 2-2                | 2                   | 2                  |           |     |        |
| H 549   | 2     | 3-3                 | 2-2                | 3                   | 2-3                |           |     |        |
| H 622   | 2     | 3-3                 | 1-1                | 2                   | 2-3                |           |     |        |
| H 504   | 2     | 3-3                 | 1-1                | 2                   | 2-1                |           |     |        |
| H 798   | 2     | 1-1                 | 0-1                | 1                   | 1-1                |           |     |        |
| J 367   | 2u    | 2-2                 | 2-1                | 3                   | 2-3                | 6/8       | 1/8 | 1/8    |
| G 486   | 2u    | 2-2                 | 2-2                | 1                   | 2-2                |           |     |        |
| J 522   | 2u    | 2-2                 | 0-0                | 2                   | 2-2                |           |     |        |
| G 722   | 2u    | 3-3                 | 2-0                | 2                   | 2-3                |           |     |        |
| H 820   | 3     | 3-3                 | 2-2                | 3                   | 2-2                |           |     |        |
| J 557   | 3     | 2-2                 | 1-0                | 2                   | 1-2*               |           |     |        |
| H 588   | 3     | 2-2                 | 2-0                | 3                   | 1-2                |           |     |        |
| J 153   | 3     | 3-3                 | 3-3                | 2                   | 3-3                | 5/8       | 0   | 3/8    |
| H 480   | 3u    | 2-2                 | 2-2                | 2                   | 3-3                | (3/8↘)    |     |        |
| J 344   | 3u    | 3-3                 | 2-0                | 3                   | 2-2                |           |     |        |
| H 710   | 3u    | 2-2                 | 2-2                | 2                   | 3-3                |           |     |        |
| J 262   | 3u    | 3-3                 | 2-2                | 3                   | 3-2                |           |     |        |

Thus, this table reveals that in the group  
 5 having been subjected to an immunization procedure by  
 the strict mucosal route, the results are substantially

12443967.032800

identical to those obtained with the negative control group. On the other hand, in the groups having been subjected to an immunization procedure by the mixed mucosal and intramuscular route or by the strict 5 intramuscular route, a marked reduction in the bacterial load is observed. This highlights the importance of the immunization conditions and in particular of the adjuvant used; consequently, the use of an adjuvant such as DC-chol, capable of promoting a 10 balanced Th1 and Th2 response, is recommended in order to obtain a protective effect.

These results are to be placed in perspective with other results relating to the serum antibody levels which are presented in Figure 3. This figure 15 shows that the immunization scheme by the strict mucosal route (1 and 1u) leads to results which are very similar to those of the negative control group. On the other hand, the immunization scheme by the mixed mucosal and intramuscular route (2 and 2u), and better 20 still the immunization scheme by the strict intramuscular route (3 and 3u), makes it possible to induce antibody levels substantially greater than those of the control group.

Thus, a high serum response may be correlated 25 with a protective effect, whereas a contrario, a low response is linked to the absence of a protective effect. The immunization conditions which make it possible to obtain the desired effect (high serum response and protective effect) include the use of the 30 parenteral route targeted in the subdiaphragmatic region or that of a Th1 adjuvant.

**Example 3: Other immunization studies in mice**

**3A- Materials and methods**

**5 Mice**

6/8-week old female Swiss mice were provided by Janvier (France). During the whole experiment, sterilized materials were used; the cages were protected by "isocaps"; the mice were fed with filtered water and irradiated food.

**Administration procedure**

During each experiment, the mice received 3 doses of the same product; each dose at 21-day intervals (days 0, 21 and 42). The administration of the product was carried out by the oral route (300 µl in 0.2 M NaHCO<sub>3</sub> by gastric gavage), or by the subcutaneous route (300 µl under the skin on the left side of the lumbar region). Ten µg of urease were administered subcutaneously and 40 µg by the oral route.

**Antigens and adjuvants**

The *H. pylori* urease apoenzyme was expressed in *E. coli* and purified as has been described in Example 5 of WO 96/31235. In the remainder of the text, the simple term of urease is used to designate this apoenzyme.

The *E. coli* heat-labile toxin (Sigma) is used as mucosal adjuvant in an amount of 1 µg/dose of urease.

QS-21 (Cambridge Biosciences) is used as adjuvant in an amount of 15 µg/dose of urease.

Bay R1005 (Bayer) is used as adjuvant in an amount of 400 µg/dose of urease.

DC-chol (R-Gene Therapeutics) is used as adjuvant in an amount of 65 µg/dose of urease.

The polyphosphazene (PCPP) (Virus Research Institute) is used as adjuvant in an amount of 100 µg/dose of urease.

5   **Challenge**

Four weeks after the second booster, the mice were subjected to a gastric gavage with 300 µl ( $3 \times 10^6$  live bacteria) of a suspension of a strain of *H. pylori* adapted to the mice and resistant to Streptomycin, the 10 strain ORV2001. One group which received no dose of antigen and which serves as control is challenged likewise.

The challenge suspension is prepared as follows: *H. pylori* is cultured on Muller-Hinton agar 15 (Difco) containing 5% sheep blood (bioMérieux) (MHA medium) which contains the following antibiotics from Sigma: Trimethoprim 5 µg/ml, Vancomycin 10 µg/ml, Polymixin B 1.3 µg/ml, Amphotericin 5 µg/ml and Streptomycin 50 µg/ml. The culture dishes are incubated 20 for 3 days at 37°C under microaerophilic conditions (Anaerocult C, Merck). This culture is harvested in order to inoculate a 75 cm<sup>2</sup> flask provided with vents (Costar) containing 50 ml of Brucella broth supplemented with 5% foetal calf serum and with the 25 abovementioned antibiotics. The flask is incubated under microaerophilic conditions, with gentle shaking for 24 hours. The suspension is then diluted in Brucella broth in order to give an OD of 0.1 at 550 nm (that is to say  $10^7$  CFU/ml).

30

**Analysis of the challenge**

Four weeks after the challenge, the mice were sacrificed by breaking the cervical vertebrae. The stomachs were removed in order to evaluate the urease 35 activity and the bacterial load by quantitative culture. A longitudinal quarter of the stomach (antrum + corpus) is used for each of the tests. The urease activity was evaluated after 4 and 24 hours (OD at

550 nm) with the Jatrox test, Procter & Gamble) and after 24 hours the number of mice still negative (OD less than 0.1) was noted.

5   **Evaluation of the infection by quantitative culture of *H. pylori***

At the time when the mice are sacrificed, the mucous membrane of a quarter of the stomach of each mouse is placed in the Portagel medium from bioMérieux 10 and then within the next two hours, transferred into a culture chamber. The sample is then homogenized using a Dounce homogenizer (Wheaton, Millville USA) containing 1 ml of Brucella medium (Brucella broth) and serially diluted up to  $10^{-3}$ . One hundred  $\mu$ l of each dilution 15 ( $10^0$ ,  $10^{-1}$ ,  $10^{-2}$  and  $10^{-3}$ ) are spread in Petri dishes containing MHA medium supplemented with the abovementioned antibiotics, for culturing at 37°C under microaerophilic conditions for 4 or 5 days. The number of viable bacteria is then counted. *H. pylori* is 20 identified by its morphology revealed by Gram staining and by positive reactions to urease, catalase and oxidase tests.

25   **Analysis of the response by ELISA**

The analyses by ELISA were performed in accordance with the standard procedure (the biotinylated conjugates and the streptavidin-peroxidase 30 were obtained from Amersham and the OPD substrate from Sigma). The plates were coated with *H. pylori* extracts (5  $\mu$ g/ml) in carbonate buffer. A control serum from mice directed against the *H. pylori* extract was introduced in each experiment. The titre corresponds to the reciprocal of the dilution giving an OD of 1.5 at 490 nm.

35

**3B- Results**

Before any comments on the subject of Figures 4 to 7, it should be noted that these figures present the

DRAFTS, 2336504500

results obtained with the antigen used with the LT adjuvant and administered by the intragastric route. This experiment is termed standard reference experiments since the prior art LT/IG combination is  
5 that which gives the best results up until now.

**Serum response**

As shown in Figure 4, after three immunizations, all the mice immunized by the  
10 subcutaneous route have a high serum IgG response. On the basis of the IgG1:IgG2a ratios, it can be noted that PCPP induces a predominant response of the Th2 type (high IgG1 level, low IgG2a level). Bay R1005 and DC-chol induce a more balanced response of the Th1/Th2  
15 type. Finally, QS-21 induces a predominant response of the Th1 type. In fact, the main difference between the four groups of mice A1 to A4 lies in their IgG2a titres, the IgG1 titres all being similar.

**20 Protection after challenge**

Figures 5 to 7 show that the level of protection in groups A1 and A2 is similar to or even better than that observed in the reference group (LT). They are groups which received doses of urease in the  
25 presence of QS-21 and of Bay R1005 respectively. Group A3 (DC-chol) shows a slightly lower level of protection. On the other hand, in group A4 (PCPP), it is not possible to demonstrate a high protective effect. It should be noted that the results presented  
30 in Figures 5 to 7 are consistent with each other.

When the results presented in Figure 4, on the one hand, and Figures 5 to 7, on the other, are compared, it can be rightly concluded that the use of an adjuvant capable of inducing a Th1 or Th1/Th2  
35 response (QS-21, Bay R1005 or DC-chol) promotes the coming into play of a protective effect, contrary to the use of a Th2-type adjuvant (PCPP).

DRAFTS, 2965000000

**Example 4: Treatment of a *H. pylori* infection in mice**

We compared the efficacy of immunization by the subcutaneous route (SC) with the mucosal route to treat a *H. pylori* infection in a mouse model.

5 OF1 mice were infected with  $10^6$  plaque forming colonies (cfu) of the *H. pylori* ORV2001 strain. After one month, it was checked that the infection was indeed established by randomly sacrificing 10/100 mice and by testing the urease activity on a quarter of the entire  
10 stomach. Given that all the results were positive, we then immunized mice (10 per group) 3 times at an interval of 3 weeks, either by the subcutaneous route using 10 µg of recombinant urease supplemented with 15 µg of QS21 (Aquila) as adjuvant or 400 µg of  
15 Bay R1005 adjuvant (Bayer), or by the oral route using 40 µg of urease mixed with 1 µg of LT. For each of the two adjuvants administered by the parenteral route, the immunization was carried out either in the neck, in order to reach the lymph nodes of the upper region of  
20 the body, or in the lumbar region in order to reach the abdominal lymph nodes. Ten mice were left noninfected and nonimmunized (negative control), whereas the mice in the positive control group received a saline solution, QS21 or Bay adjuvant by the subcutaneous  
25 route (lumbar region).

One month after the third immunization, all the mice were sacrificed and the stomachs removed in order to evaluate the extent of colonization by measuring the urease activity (10/10 mice were analysed in each  
30 group) and by carrying out a quantitative culture (5/10 mice were analysed). Figures 6A (test on urease) and 6B (culture) show that in mice immunized with urease supplemented with QS21 as adjuvant by the subcutaneous route in the lumbar region, the infection  
35 had practically disappeared (4/5 mice were negative in quantitative culture). The mice immunized with urease by the subcutaneous route in the neck, in the presence of QS21 and the mice receiving urease plus LT by the

oral route exhibited a reduction in infection of 10 to 100 relative to the nonimmunized mice. The Bay adjuvant had induced an identical reduction, which was more pronounced in mice immunized in the lumbar region.

5        A histopathology performed on these same mice did not reveal a more severe gastritis compared with the controls.

10      As was observed in our previous prophylactic study (Example 1), the protected mice exhibited a high serum level for the two isotypes IgG1 and IgG2, which is representative of a balanced Th2/Th1 response. Furthermore, the mice immunized by the subcutaneous route in the lumbar region exhibited the highest serum IgA levels, which demonstrates a mucosal response.

15      These results indicate that targeted systemic immunization is capable of curing a *H. pylori* infection acquired in a mouse, and that the use of adjuvants inducing a Th1/Th2-type balanced mucosal response is desirable in order to achieve this aim.


Claims

1. Pharmaceutical composition which comprises an immunogenic agent derived from *Helicobacter* and at least one compound selected from:

5 (i) saponins purified from an extract of *Quillaja saponaria*;

10 (ii) cationic lipids or a salt of the latter; the said lipids being weak inhibitors of protein kinase C and having a structure which includes a lipophilic group derived from cholesterol, a bonding group selected from carboxyamides and carbamoyls, a spacer arm consisting of a branched or unbranched linear alkyl chain of 1 to 20 carbon atoms, and a cationic amine group selected from primary, secondary, tertiary and quaternary amines, on condition that these lipids are not provided in the form of liposomes when the said composition contains no saponin or glycolipopeptide of formula (I); and

15 (iii) glycolipopeptides of formula (I):



in which

25  $\text{R}^1$  represents an alkyl residue saturated or unsaturated once or several times and comprising from 1 to 50 carbon atoms,

30  $\text{X}$  represents  $-\text{CH}_2-$ ,  $-\text{O}-$  or  $-\text{NH}-$ ,

$\text{R}^2$  represents a hydrogen atom or an alkyl residue saturated or unsaturated once or

several times and comprising from 1 to 50 carbon atoms,

- 5      R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> each represent, independently of each other, a hydrogen atom or an acyl-CO-R<sup>6</sup> residue in which R<sup>6</sup> represents an alkyl residue having from 1 to 10 carbon atoms,
- 10     R<sup>7</sup> represents a hydrogen atom, a C<sub>1</sub>-C<sub>6</sub> alkyl, hydroxymethyl, 1-hydroxyethyl, mercaptomethyl, 2-(methylthio)ethyl, 3-aminopropyl, 3-ureidopropyl, 3-guanidylpropyl, 4-aminobutyl, carboxymethyl, carbamoylmethyl, 2-carboxyethyl, 2-carbamoylethyl, benzyl, 4-hydroxybenzyl, 3-indolylmethyl or 4-imidazolylmethyl group,
- 15     R<sup>8</sup> represents a hydrogen atom or a methyl group, and
- 20     R<sup>9</sup> represents a hydrogen atom, an acetyl, benzoyl, trichloroacetyl, trifluoroacetyl, methoxycarbonyl, t-butyloxycarbonyl or benzyloxycarbonyl group, and
- 25     R<sup>7</sup> and R<sup>8</sup> may, when they are taken together, represent a -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>- group.
- 30     2. Composition according to Claim 1, which comprises at least two compounds, a first compound being selected from the saponins purified from an extract of *Quillaja saponaria* and a second compound being selected from cationic lipids or a salt of the latter; the said lipids being weak inhibitors of protein kinase C and having a structure which includes a lipophilic group derived from cholesterol, a bonding

group selected from carboxyamides and carbamoyls, a spacer arm consisting of a branched or unbranched linear alkyl chain of 1 to 20 carbon atoms, and a cationic amine group selected from primary, secondary, 5 tertiary and quaternary amines.

3. Composition according to Claim 1 or 2, in which the compound is a saponin which is the QS-21 fraction purified from a *Quillaja saponaria* extract.

4. Composition according to Claim 1 or 2, in which 10 the compound is a cationic lipid made in the form of a dispersion.

5. Composition according to Claim 1, 2 or 4, in which the compound is a cationic lipid which is 3-beta-[N-(N',N'-dimethylaminoethane)carbamoyl]cholesterol(DC-15 chol) or a salt of the latter.

6. Composition according to Claim 1, in which the compound is a glycolipopeptide which is N-(2-L-leucin-amido-2-deoxy- $\beta$ -D-glucopyranosyl)N-octadecyl-dodecanoyleamide (Bay R1005).

20 7. Composition according to one of Claims 1 to 6, in which the immunogenic agent derived from *Helicobacter* is selected from a preparation of inactivated *Helicobacter* bacteria, a *Helicobacter* cell lysate, a peptide and a polypeptide from *Helicobacter* 25 in purified form.

8. Composition according to Claim 7, in which the immunogenic agent derived from *Helicobacter* is the UreB or UreA subunit of *Helicobacter* urease.


9. Composition according to one of Claims 1 to 8, 30 in which the immunogenic agent is derived from *Helicobacter pylori*.

10. Use of an immunogenic agent derived from *Helicobacter* and of at least one compound selected from:

35 (i) saponins purified from an extract of *Quillaja saponaria*;

(ii) cationic lipids or a salt of the latter; the said lipids being weak inhibitors of protein kinase C and having a structure which includes a lipophilic group derived from cholesterol, a bonding group selected from carboxyamides and carbamoyls, a spacer arm consisting of a branched or unbranched linear alkyl chain of 1 to 20 carbon atoms, and a cationic amine group selected from primary, secondary, tertiary and quaternary amines, on condition that these lipids are not provided in the form of liposomes when the said composition contains no saponin or glycolipopeptide of formula (I); and

(iii) glycolipopeptides of formula (I):



in which

R<sup>1</sup> represents an alkyl residue saturated or unsaturated once or several times and comprising from 1 to 50 carbon atoms,

X represents -CH<sub>2</sub>-, -O- or -NH-,

R<sup>2</sup> represents a hydrogen atom or an alkyl residue saturated or unsaturated once or several times and comprising from 1 to 50 carbon atoms,

R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> each represent, independently of each other, a hydrogen atom or an acyl-CO-R<sup>6</sup> residue in which R<sup>6</sup> represents an alkyl

103250 79500460

residue having from 1 to 10 carbon atoms,

- 5            R<sup>7</sup>            represents a hydrogen atom, a C<sub>1</sub>-C<sub>7</sub> alkyl, hydroxymethyl, 1-hydroxyethyl, mercaptomethyl, 2-(methylthio)ethyl, 3-aminopropyl, 3-ureidopropyl, 3-guanidylpropyl, 4-aminobutyl, carboxymethyl, carbamoylmethyl, 2-carboxyethyl, 2-carbamoyethyl, benzyl, 4-hydroxybenzyl, 3-indolylmethyl or 4-imidazolylmethyl group,
- 10           R<sup>8</sup>            represents a hydrogen atom or a methyl group, and
- 15           R<sup>9</sup>            represents a hydrogen atom, an acetyl, benzoyl, trichloroacetyl, trifluoroacetyl, methoxycarbonyl, t-butyloxycarbonyl or benzyloxycarbonyl group, and
- 20           R<sup>7</sup> and R<sup>8</sup>    may, when they are taken together, represent a -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>- group;
- 25           in the manufacture of a pharmaceutical composition capable of inducing a T helper 1 (Th1) type immune response against *Helicobacter*.
11.          Use according to Claim 10, of an immunogenic agent derived from *Helicobacter* and of at least two compounds, a first compound being selected from the saponins purified from an extract of *Quillaja saponaria* and a second compound being selected from cationic lipids or a salt of the latter; the said lipids being weak inhibitors of protein kinase C and having a structure which includes a lipophilic group derived from cholesterol, a bonding group selected from carboxyamides and carbamoyls, a spacer arm consisting

of a branched or unbranched linear alkyl chain of 1 to 20 carbon atoms, and a cationic amine group selected from primary, secondary, tertiary and quaternary amines.

5 12. Use according to Claim 10 or 11, in which the compound is a saponin which is the QS-21 fraction purified from a *Quillaja saponaria* extract.

10 13. Use according to Claim 10 or 11, in which the compound is a cationic lipid made in the form of a dispersion.

14. Use according to Claim 10, 11 or 13, in which the compound is 3-beta-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-chol) or a salt of the latter.

15 15. Use according to Claim 10, in which the compound is a glycolipopeptide which is N-(2-L-leucin-amido-2-deoxy- $\beta$ -D-glucopyranosyl) N-octadecyl-dodecanoyleamide (Bay R1005).

20 16. Use according to one of Claims 10 to 15, in which the Th1 type immune response is measured in mice and is characterized either (i) by a ratio of the ELISA IgG2a : IgG1 titres greater than or equal to 1 : 100 or (ii) by a ratio of the ELISA IgG2a : IgA titres greater than or equal to 1 : 100.

25 17. Use according to Claim 16, in which the Th1 type immune response is measured in mice and is characterized either (i) by a ratio of the ELISA IgG2a : IgG1 titres greater than or equal to 1 : 10 or (ii) by a ratio of the ELISA IgG2a : IgA titres greater than or equal to 1 : 10.


30 18. Use according to Claim 17, in which the Th1 type immune response is measured in mice and is characterized either (i) by a ratio of the ELISA IgG2a : IgG1 titres greater than or equal to 1 : 2 or (ii) by a ratio of the ELISA IgG2a : IgA titres greater than or equal to 1 : 2.

35 19. Use according to one of Claims 10 to 18, in which the immunogenic agent derived from *Helicobacter*


is selected from a preparation of inactivated *Helicobacter* bacteria, a *Helicobacter* cell lysate, a peptide and a polypeptide from *Helicobacter* in purified form.

- 5 20. Use according to Claim 19, in which the immunogenic agent derived from *Helicobacter* is the UreB or UreA subunit of *Helicobacter* urease.
- 10 21. Use according to one of Claims 10 to 20, in which the immunogenic agent is derived from *Helicobacter pylori*.
22. Use according to one of Claims 10 to 21, in which the pharmaceutical composition is intended to be administered by the systemic route.
- 15 23. Use according to Claim 22, in which the pharmaceutical composition is intended to be administered by the strict systemic route.
24. Use according to Claim 22 or 23, in which the pharmaceutical composition is intended to be administered by the systemic route in the part of a mammal, in particular of a primate, situated under its diaphragm.
- 20 25. Use according to one of Claims 22 to 24, in which the pharmaceutical composition is intended to be administered by a systemic route in the dorsolumbar region of a mammal, in particular a primate.
26. Use according to one of Claims 22 to 25, in which the pharmaceutical composition is intended to be administered by a systemic route selected from the subcutaneous route, the intramuscular route and the 30 intradermal route.
27. Use according to one of Claims 10 to 26, in which the pharmaceutical composition is intended to be administered twice or three times by the systemic route during the same treatment, to prevent or treat a 35 *Helicobacter* infection.
28. Conjoint use of an immunogenic agent derived from *Helicobacter* and of a compound capable of promoting the induction of a T helper 1 (Th1) type

immune response against *Helicobacter*, in the manufacture of a pharmaceutical composition intended to be administered by the systemic route to prevent or treat a *Helicobacter* infection.

Figure 1

008230-230000

Figure 2

09/403967 - 00875

Figure 3




Figure 4





Figure 5

PCT/FR98/00875

Figure 6




Figure 7





Figure 8A and 8B

## COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled ANTI-*HELICOBACTER* VACCINE COMPOSITION COMPRISING A TH1-TYPE ADJUVANT, the specification of which

- is attached hereto.  
 was filed on November 1, 1999 as Application Serial No. 09/403,967  
and was amended on \_\_\_\_\_.  
 was described and claimed in PCT International Application No. \_\_\_\_\_  
filed on \_\_\_\_\_ and as amended under PCT Article 19 on \_\_\_\_\_.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56(a).

**FOREIGN PRIORITY RIGHTS:** I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

| Country | Serial Number  | Filing Date | Priority Claimed? |
|---------|----------------|-------------|-------------------|
| France  | 97/05,608      | 30/04/97    | Yes               |
| France  | 97/15,732      | 08/12/97    | Yes               |
| PCT     | PCT/FR98/00875 | 30/04/98    | No                |

**PROVISIONAL PRIORITY RIGHTS:** I hereby claim priority benefits under Title 35, United States Code, §119(e) and §120 of any United States provisional patent application(s) listed below filed by an inventor or inventors on the same subject matter as the present application and having a filing date before that of the application(s) of which priority is claimed:

| Serial Number | Filing Date | Status |
|---------------|-------------|--------|
|               |             |        |

**COMBINED DECLARATION AND POWER OF ATTORNEY**

**NON-PROVISIONAL PRIORITY RIGHTS:** I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(e) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

| Serial Number | Filing Date | Status |
|---------------|-------------|--------|
|               |             |        |

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Paul T. Clark, Reg. No. 30,162, Karen L. Elbing, Ph.D. Reg. No. 35,238, Kristina Bieker-Brady, Ph.D. Reg. No. 38,109, Susan M. Michaud, Ph.D. Reg. No. 42,885, Mary Rose Scozzafava, Ph.D., Reg. No. 36,268, James D. DeCamp, Ph.D., Reg. No. 43,580.

Address all telephone calls to: Paul T. Clark at 617/428-0200.

Address all correspondence to: Paul T. Clark at Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

|                                    |   |   |                            |
|------------------------------------|---|---|----------------------------|
| Full Name<br>(First, Middle, Last) | Residence Address<br>(City, State, Country) | Post Office Address<br>(Street, City, State, Country) | Citizenship                |
| <u>Bruno Guy</u>                   | <u>Lyon, France</u> <u>Fix</u>              | 15B, rue des Noyer,<br>F-69005, Lyon, France          |                            |
| Signature:                         | <u>Bruno Guy</u>                            |   | <u>9 Nov 1999</u><br>Date: |

COMBINED DECLARATION AND POWER OF ATTORNEY

|                                    |   |   |                |
|------------------------------------|---|---|----------------|
| Full Name<br>(First, Middle, Last) | Residence Address<br>(City, State, Country)   | Post Office Address<br>(Street, City, State, Country)                         | Citizenship    |
| Jean Haensler                      | Saint Genis les Ollières<br>France <i>Fix</i> | Bâtiment B, 17, rue<br>Piccandet, F-69290 Saint<br>Genis les Ollières, France |                |
| Signature:                         | <i>Jean Haensler</i>                          |   | Date: 9 Nov 99 |

008330-7953404494010